リウマチ病セミナー XIV

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,510 円(税込)

購入する

商品紹介

感染性疾患は古来リウマチ学の主要なテーマであるが、なかでも連鎖球菌性関節炎は症状が敗血症から反応性関節炎に至るまで幅広く、リウマチ病との深い関係日常の診療で再認識する必要があると思われる。（序文より）

目次

  • 表紙
  • 執筆者一覧
  • 序文
  • 目次
  • 炎症リウマチ
  • 連鎖球菌性関節炎
  • ヘモクロマトーシス
  • 全身性エリテマトーデス,抗リン脂質抗体症候群,RAと粥状硬化症
  • RAと低補体価
  • 骨関節,脊椎,神経
  • myositis ossificans
  • 変形性関節症における軟骨下骨の変化とその病態
  • 輪状披裂関節の病態
  • Fibromyalgia(2002) その診断と治療
  • 関節リウマチとうつ病
  • 燐・カルシウム代謝
  • ank gene
  • マグネシウムとカルシウムの恒常性維持
  • DHEAと骨粗鬆症
  • 血管石灰化と骨粗鬆症
  • 検査法
  • Anti Citrulline-Containing Peptide Antibody
  • 生物学的反応
  • オステオポンチンと骨吸収性疾患
  • Prostate cancer cell linesとmineralisation
  • 治療と副作用
  • 変形性膝関節症のリハビリテーション(薬剤,手術によらない)効果
  • 骨・関節疾患に対するextracorporeal shockwave therapy
  • 関節炎とエクササイズの効果
  • 下肢静脈還流障害の臨床と深部静脈血栓症
  • PPAR-γリガンドによる関節炎治療
  • 膠原病に伴う難治性皮膚潰瘍の成因と治療
  • 脊椎疾患に対する遺伝子治療の試み
  • 更年期後骨粗鬆症に対する新しい治療法
  • 関節リウマチと閉塞性睡眠障害
  • X線よりみた関節リウマチ患者の関節再建術の必要性
  • 関節リウマチと相補代替医療
  • 手の装具療法
  • リコンビナントBMPの臨床応用と問題点
  • 手術
  • リウマチ肘に対する人工関節手術
  • ロボット手術-コンピュータ支援手術-
  • 索引(XIV)
  • 総索引(I～XIV)
  • Drug Information
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.7 掲載の参考文献
1) Dubost JJ, Soubrier M, De Champs C, et al:No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. Ann Rheum Dis 61:267-269, 2002
 
2) McCormack JM, Crossley CA, Ayoub EM, et al:Poststreptococcal anti-myosin antibody idiotype associated with systemic lupus erythematosus and Sjogren's syndrome. J Infect Dis 168:915-921, 1993
PubMed
3) Neff L, Zeisel M, Sibilia J, et al:NF-kappaB and the MAP kinases/AP-1 pathways are both involved in interleukin-6 and interleukin-8 expression in fibroblast-like synoviocytes stimulated by protein I/II, a modulin from oral streptococci. Cell Microbiol 3:703-712, 2001
 
4) Li EK:Rheumatic disorders associated with streptococcal infections. Bailliere Clin Rheumatol 14:559-578, 2000
 
5) Sokol MS, Ward PE, Tamiya H, et al:D8/17 expression on B lymphocytes in anorexia nervosa. Am J Psychiatry 159:1430-1432, 2002
 
6) Stollerman GH:Rheumatic fever in the 21st century. Clin Infect Dis 33:806-814, 2001
PubMed
7) Abdel-Rehim M, Degnan B, El-Ghobary A, et al:Serum antibodies to group A streptococcal extracellular and cell-associated antigens in Egyptians with post-streptococcal diseases. FEMS lmmunol Med Microbiol 31:21-27, 2001
 
8) Goldsmith DP, Long SS:Streptococcal disease of childhood; a changing syndrome [abstract]. Arthritis Rheum 25 (supplement 4):S18-S18, 1982
 
9) Iglesias-Gamarra A, Mendez EA, Cuellar ML, et al:Poststreptococcal reactive arthritis in adults:Long-term follow-up. Am J Med Sci 321:173-177, 2001
PubMed
10) Jansen TLThA, Janssen M, Traksel R, et al:A clinical and serological comparison of group A versus non-group A streptococcal reactive arthritis and throat culture negative cases of post-streptococcal reactive arthritis. Ann Rheum Dis 58:410-414, 1999
 
11) Ahmed S, Ayoub EM, Scornik JC, et al:Poststreptococcal reactive arthritis. Clinical characteristics and association with HLA-DR allels. Arthritis Rheum 41:1096-1102, 1998
 
12) Ayoub EM, Majeed HA:Poststreptococcal reactive arthritis. Curr Opin Rheumatol 12:306-310, 2000
PubMed
13) Visser H, Speyer I, Ozcan B, et al:The diagnostic value of streptococcal serology in early arthritis; a prospective cohort study. Rheumatol 39:1351-1356, 2000
 
P.15 掲載の参考文献
1) 高橋忠雄:わが国における肝蓄積症, 最新医学 24:128, 1969.
 
2) Axford JS, Bomford AB, Revell P, Watt I, Hamilton EDB:A case of hemochromatosis arthritis. Br J Rheumatol 31:547-553, 1992.
 
3) Axford JS:Rheumatic manifestations of haemochromatosis. Bailliers Clinical Rheumato 15:351-365, 1991.
 
4) 林紀夫ほか:ヘモクロマトーシス. 内科学書, 改訂第5版 (島田馨編), pp1764-1765, 場所, 出版社.
 
5) Walker RJ, Dymock IW, Ansell ID, et al:Synovial biopsy in haemochromatosis arthropathy. Histological findings and iron deposition in relation to total body iron overload. Ann Rheum Dis 31:98-102, 1971.
 
6) Feder JN, Gnirke A, Thomas W, et al:A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399-408, 1996.
 
7) Olynyk JK, Cullen DJ, Aquilia S, et al:A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341:718-724, 1999.
 
8) Li J, Zhu Y, Singal DP:HFE gene mutations in patients with rheumatoid arthritis. J Rheumatol 27:2074-2077, 2000.
 
9) Willis G, Scott DGI, Jennings BA, et al:HFE mutations in an inflammatory arthritis. Rheumatology 41:176-179, 2002.
 
10) Fleming RE, Sly WS:Mechanisms of iron accumulation in hereditary hemochromatosis, Annu Rev Physiol 64:663-680, 2002.
PubMed
11) 塩沢俊一:膠原病学. 東京, 丸善, 2003.
 
12) Britton RS, Leicester KL, Bacon BR:Iron toxicity and chelation therapy. Int J Hematol 76:219-228, 2002.
PubMed
13) Conrad ME, Umbreit JN, Moore EG, et al:Hereditary hemochromatois:aprevalent disorder of iron metabolism with an elusive etiology. Am J Hematol 47:218-224, 1994.
 
14) McDonnell SM, Preston BL, Jewell SA, et al:Asurvey of 2,851 patients with hemochromatosis:symptoms and response to treatment. Am J Med 106:619-624, 1999.
 
15) Adams PC, Kertesz AE, Valberg LS:Clinical presentation of hemochromatosis:a changing scene. Am J Med 90:445-449, 1991.
PubMed
16) Adams PC, Speechley M:The effect of arthritis on the quality of life in hereditary hemochromatosis. 23:707-710, 1996.
PubMed
17) Axford JS, Bomford A, Revell P, et al:Hip arthropathy in genetic hemochromatosis. Arthritis Rheum 34:357-361,1991.
PubMed
18) Schumacher HR Jr:haemochromatosis. Baillers Clinical Rheumatol 14:277-284,2000.
PubMed
19) Espinosa-Morales R, Escalante A:Diagnostic confusion caused by hepatitis C:hemochromatosis presenting as rheumatoid arthritis. J Rheumatol 25:2459-63, 1998.
PubMed
20) Jager HJ, Mehring U-M, Gotz GF, et al:Radiologic features of the visceral and skeletal involvement of hemochromatosis. Eur Radiol 7:1199-1206, 1997.
 
21) Yapp TR, Eijkelkamp EJ, Powell LW. Population secreening for HFE-associated haemochromatosis:should we have to pay for our genes? Intern Med J 31:48-52, 2001.
 
22) Chales G, Guggenbuhl P:When and how we screen for hereditary hemochromatosis Joint Bone Spine 70:263-270, 2003.
PubMed
P.23 掲載の参考文献
1) Bulkley BH, Roberts WC:The heart in SLE and the changes induced in it by corticosteroid therapy:a study of 36 necropsy cases. Am J Med 53:243-264, 1975
 
2) Urowitz MB, Bookman AA, Koehler BE, et al:The bimodal mortality pattern of SLE. Am J Med 60:221-225,1976
PubMed
3) Petri M, Perez-Gutthann S, Spence D, et al:Risk factors for coronary artery disease in patients with SLE. Am J Med 93:513-519, 1992
PubMed
4) Manzi S, Meilahn EN, Rairie JE, et al:Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus:comparison with the Framingham study. Am J Epidemiol 145:408-415,1997
PubMed
5) Esdaile JM, Abrahamowicz M, Grodzicky T, et al:Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:233-2337,2001
 
6) 日本脳神経超音波学会 頸動脈エコー検査ガイドライン作成委員会:頸動脈エコーによる動脈硬化性病変評価のガイドライン (案) Neurosonology 15:20-33,2002
Medical*Online
7) Svenungsson E, Urstad KJ, Heimb rger M, et al:Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887-1893, 2001
 
8) Salonen JT, Yla-Herttuala S, Yamamoto R, et al:Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-887,1992
 
9) Park YB, Ahn CW, Choi HK, et al:Morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 46:1714-1719,2002
PubMed
10) Kumeda Y, Inaba M, Goto H, et al:Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 46:1489-1497,2002
PubMed
11) George J, Haratz D, Shoenfeld Y:Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome. Reumatic Disease Clinics 27:603-610,2001
 
12) George J, Afek A, Gilburd B, et al:Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β-glycoprotein I. Circulation 98:1108-1115,1998
 
13) George J, Harats D, Gilburd B, et al:Adoptive transfer of β2-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102:1822-1827,2000
 
14) Wick G, Schett G, Amberger A, et al:Is atherosclerosis an immunologically mediated disease? Immunol Today 16:27-33, 1995
PubMed
15) 久米典昭:酸化LDLと動脈硬化. 日老医誌 38:447-451, 2001
 
P.27 掲載の参考文献
1) Wang Y, Kristan J, Hao L, et al:A role for complement in antibody-mediated inflammation:C5-C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J Immunol 164:4340-4347, 2000
PubMed
2) Brodeur JP, Ruddy S, Schwartz LB, et al:Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Reum 34:1531-1537, 1991
 
3) Neumann E, Barnum SR, Tarmer IH, et al:Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum 46:934-945, 2002
 
4) Saraux A, Bourdon V, Devaucchelle JH, et al:Is hypocomplementemia useful for diagnosing or predicting extra-articular manifestations in patients with rheumatoid arthritis. Joint Bone Spine 68:487-492, 2001
PubMed
5) Mongan ES, Cass RM, Jacox RF, et al:A study of the relation of seronegative and seropositive rheumatoid arthritis to each other and to necrotizing vasculitis. Am J Med 47:23-35, 1969
PubMed
6) Franco A, Schur PH:Hypocomplementemia in rheumaoid arthritis. Arthritis Rheum 1:231-238, 1971
 
7) Hunder GG, Mcduffie FC:Hypocomplementemia rheumatoid arthritis. Am J Med 54:461-472, 1973
PubMed
8) Theomopoulos AN, et al:IgM rheumatoid factor and low molecular weight of IgM. An association with vasculitis. Arthritis Rheum 17:272-284, 1974
PubMed
9) Scott DGI, Bacon PA, Tribe CR:Systemic rheumatoid vasculitis. A clinical and laboratory study of 50 cases. Medicine 60:288-296, 1981
 
10) Stage DE, Manni RM:7S gamma M-globulin in rheumatoid arthritis. Arthritis Rheum 14:440-450, 1971
 
11) 矢田純一:補体の機能と活性化経路. 日本臨牀57 (増刊):31-34, 1999
 
12) 小林賢一, 玉井誠一:免疫複合体とその検出方法. 日本臨牀57 (増刊):85-89, 1999
 

骨関節,脊椎,神経

P.34 掲載の参考文献
1) Schajowicz F:Tumors and tumorlike lesions of bone. 2nd ed, pp581-590, Berlin, Heidelberg, Springer-Verlag, 1994
 
2) Rosenberg AE:Myositis ossificans and fibroosseous pseudotumor of digits. In:World Health Organization Classification of Tumors. Pathology and genetics of tumours of soft tissue and bone. (eds, FletcherCDM, Unni K, Mertens F):52-54, IARC Press, Lyon, 2002
 
3) Smith R:Fibrodysplasia (myositis) ossificans progressiva. Clinical lessons from rare disease. Clin Orthop 346:7-14, 1998
PubMed
4) Cohen M:Bone morphogenetic proteins with some comments on fibrodysplasia ossificans progressiva and NOGGIN. Am J Med Gennet 109:87-92, 2002
 
5) Gannon FH, Valentine BA, Shore EM, et al.:Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin Orthop 346:19-25, 1998
 
6) Shafritz AB, Shore EM, Gannon FH, et al.:Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 335:555-561, 1996
PubMed
7) Feldman G, Li M, Martin S, et al.:Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Hum Genet 66:128-135, 2000
PubMed
8) 寺井秀富, 高岡邦夫:BMP. リウマチ病セミナーXIV (七川歡次監修), pp238-242, 大阪, 永井書店, 2003
 
9) Kaplan FS, Shore EM, Zasloff MA:Fibrodysplasia Ossificans Progressiva:Searching for the skeleton key. Calcif Tissue Int 59:75-78, 1996
PubMed
10) Shore EM, Glaser DL, Gannon FH:Osteogenic induction in hereditary disorders of heterotopic ossification. Clin Orthop 374:303-316, 2000
PubMed
11) Matsumoto K, Matsuda T, Hukuda S:Osteoma cutis associated with disordered ossification of the clavicle. A case report. Clin Orthop 246:106-110, 1989
PubMed
12) Degryse HR, AparisiF:Extraskeletal cartilaginous and osseous tumors. In:Imaging of soft tissue tumors, 2nd ed. (Ed, De Schepper AM), pp343-351, Berlin Heidelberg New York, Springer-Verlag, 2001
 
13) Ahrengart L:Periarticular heterotopic ossification after total hip arthroplasty. Risk factors and consequences. Clin Orthop 263:49-58, 1990
 
14) Dejerine-KlumpkeA, Ceillier A:Paraosteoarthropathies of paraplegic patients by spinal cord lesion. Clinical and roentgenographic study. Ann Med 5:497, 1918, Clin Orthop 263:3-12, 1991
 
15) Garland DE:A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop 263:13-29, 1991
PubMed
16) Ackerman LV:Extra-osseous localized non-neoplastic bone andcartilage formation (so-called myositis ossificans). J Bone and Joint Surg 40-A:279-298, 1958.
 
17) Spjut HJ, Dorfman HD:Florid reactive periostitis of the tubular bones of the hands and feet. Am J Surg Pathol 5:423-433, 1981.
PubMed
18) Nora FE, Dahlin DC, Beabout JW:Bizarre parosteal osteochondromatous proliferations of the hands and feet. Am J Surg Pathol 7:245-250, 1983.
PubMed
19) Meneses MF, Unni KK, Swee RG:Bizarre parosteal osteochondromatous proliferation of bone (Nora's lesion). Am J Surg Pathol 17:691-697, 1993
 
20) Dupree WB, Enzinger FM:Fibro-osseous pseudotumor of the digits. Cancer 58:2103-2109, 1986
PubMed
21) Miller-Breslow A, Dorfman HD:Dupuytren's (subungual) exostosis. Am J Surg Pathol 12:368-378, 1988.
PubMed
22) Dal Cin P, Pauwels P, Poldermans LJ:Clonal chromosome abnormalities in a so-called Dupuytren's subungual exostosis. Genes, Chromosomes & Cancer 24:162-164, 1999
 
23) Oglivie-Harris DJ, Hons CH B, Fornasier VL:Pseudomalignant myositisossificans:Heterotopic new-bone formation without a history of trauma. J Bone and Joint Surg 62-A:1274-1283, 1980
 
24) 日本整形外科学会 骨・軟部腫瘍委員会 編:悪性骨腫瘍取扱い規約, 第3版:151-153. 東京, 金原出版, 2000
 
25) Sundaram M, Wang LL, Rotman M, et al.:Florid reactive periostitis and bizarre parosteal osteochondromatous proliferation:pre-biopsy imaging evolution, treatment and outcome. Skeletal Radiol 30:192-198, 2001
 
26) Konishi E, Kusuzaki K, Murata H, et al.:Extraskeletal osteosarcoma arising in myositis ossificans. Skeletal Radiol 30:39-43, 2001
PubMed
27) Choi JH, Gu MJ, Kim MJ, et al.:Fibrosarcoma in bizarre parosteal osteochondromatous proliferation. Skeletal Radiol 30:44-47, 2001
PubMed
28) Brantus JF, Meunier PJ:Effects of intravenous etidronate and oral corticosteroids in fibrodysplasia ossificans progressiva. Clin Orhop 346:117-120, 1998
PubMed
29) Zasloff MA, Rocke DM, Crofford LJ, et al.:Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin. Clin Orthop 346:121-129, 1998
PubMed
30) Kjaersgaard-Andersen P, Schmidt SA:Total hip arthroplasty. The role of antiinflammatory medications in the prevention of heterotopic ossification. Clin Orthop 263:78-86, 1991
PubMed
31) Matsumoto K, Hukuda S, Ishizawa M, et al.:Bizarre parosteal osteochondromatous proliferation (BPOP) of bone:Report of two cases treated with EHDP. 関外誌 16:327-332, 1997
 
32) Ayers DC, Pellegrini VD, McCollister Evarts C:Prevention of heterotopic ossification in high-risk patients by radiation therapy. Clin Orthop 263:87-93, 1991
 
P.41 掲載の参考文献
1) Buu DB, Schather MB:The involvement of subchondral mineralized tussure in osteoarthrosis; quntitative microscopic evidence. Microsc Res Tech 37:343-357, 1997
 
2) Bailey AJ, Mansell Jp:Do subchondral bone changes exacerbate or precede articular cartilage destruction in osteoarthritis of the elderly? Gerontology 43:296-304, 1997
 
3) Mankin HJ, Dorfman H, Lippiello L, et al:Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 53:523-537, 1971
 
4) Fernandes JC, Martel-Pelletier J, Pelletier JP:The role of cytokines in osteoarthritis pathophysiology. Biorheology 39:237-246, 2002
PubMed
5) Yoshihara Y, Nakamura H, Obata K, et al:Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455-461, 2000
PubMed
6) Dean DD, Martel-Pelletier J, Pelletier Jp, et al:Evidence for ietalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84:678-685, 1989
PubMed
7) von der Mark K, Kirsch T, Nerlich A, et al:Type X collagen synthesis in human asteoarthritic cartilage. Indication of chondrocyte hypertrophy. Arthritis Rheum 35:806-811, 1992
PubMed
8) Mankin HJ, Lippiello L:The glycosaminoglycans of normal and arthritic cartilage. J Clin Invest 50:1712-1719, 1971
PubMed
9) Dieppe P, Cushnaghan J, Tucker M, et al:The Bristol 'OA500 study':progression and impact of the disease after 8 years. Osteoarthritis Cartilage 8:63-68, 2000
PubMed
10) Yamada K, Healey R, Amiel D, et al:Subchondral bone of the human knee joint in aging and osteoarthritis Osteoarthritis Cart 10:360-369, 2002
 
11) Brandt KD, Schauwecker DS, Dansereau S, et al:Bone scintigraphy in the canine cruciate deficiency model of osteoarthritis. Comparison of the unstable and contralateral knee. J Rheumatol 24:140-145, 1997
 
12) Pastoureau PC, Chomel AC, BOnnet J:Evidence of early subchondral bone changes in the meniscectomized guinea pig. A densitometric study using dual-energy X-ray absorptiometry subregional analysis. Osteoarthritis Cartilage 7:466-473, 1999
PubMed
13) Newberry WN, Zukosky DK, Haut RC:Subfracture insult to a knee joint causes alterations in the bone and in the functional stiffness of overlying cartilage. J Orthop Res 15:450-455, 1997
PubMed
14) Watson PJ, Carpenter TA, Hall LD, et al:Cartilage swelling and loss in a spontaneous model of osteoarthritis visualized by magnetic resonance imaging. Osteoarthritis Cart 4:197-207, 1996
 
15) Carlson CS, Loeser RF, Purser CB, et al:Osteoarthritis in cynomolgus macaques. III. Effecs of age, gender, and subchondral bone thicness on the severity of disease. J Bone Miner Res 11:1209-1217, 1996
 
16) Li B, Aspden RM:Composition and mechanical properties of cancelous bone from the femoral head of patients with osteoporosis and osteoarthritis. J Bone Miner Res 12:641-651, 1997
PubMed
17) Fazzalari NL, Parkinson IH:Fractal properties of subchondral candelous bone in severe osteoarthritis of the hip. J Bone Miner Res 12:632-640, 1997
PubMed
18) Dequeker J, Mohan S, Finkelman RD, et al:Generalized osteoarthritis associated with increased insulin-like growth factor types I and II and transforming growth factor beta in cortical bone fromthe iliac crest. Possible mechanism of increased bone density and protection against osteoporosis. Arthritis Rheum 36:1702-1708 1993
 
19) Lloyd ME, Hart DJ, Nandra D, et al:Relation between insulin-like growth factor-I concentrations, osteoarthritis, bone density, and fractures in the general population:the Chingford study. Ann Rheum Dis 55:870-874, 1996
PubMed
20) Middleton JF, Tyler JA:Upregulation of insulin-like growth factor I gene expression in the lesions of osteoarthritic human articular cartilage. Ann Rheum Dis 51:440-447, 1992
PubMed
21) Westacott CI, Webb GR, Warnock MG, et al:Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis Rheum 40:1282-1291, 1997
PubMed
22) Takahashi K, Kubo T, Kobayashi K, et al:Hydrostatic pressure influences mRNA expression of transforming growth factor b1 and heat shock protein 70 in chondrocyte-like cell line. J Orthop Res 15:150-158, 1997
 
23) Takahashi K, Kubo T, Arai Y, et al:Hydrostatic pressure induces expression of interleukin 6 and tumor necrosis factor mRNAs in a chondrocyte-like cell line. Ann Rheum Dis 57:231-236, 1998
 
24) Kubo T, Kitajima I, Takahashi K, et al:Interleukin 8 is produced by hydrostatic pressure in human osteoblast cell line, MG-63. Pathophysiology 5:199-204, 1998
 
25) Kubo T, Arai Y, Takahashi K, et al:Effect of pressure loading on interleukin-8 production in chondrocytes. Pathophysiology 6:35-39, 1999
 
P.47 掲載の参考文献
1) Montgomery WW:Cricoarytenoid arthritis. Laryngoscope 73:801-836, 1961
 
2) 颯田琴次, 阿部重男:慢性関節レウマチスに併発せる環状披裂関節強直症の一例. 大日耳鼻 35:1155, 1929
 
3) Grossman A, Martin JR, Root HS:Rheumatoid arthritis of the cricoarytenoid joint. Laryngoscope 71:530-544, 1961
 
4) Montgomery WW:Incidence of laryngeal involvement in rheumatoid arthritis. New Eng J Med 4:193-195, 1962
 
5) Bienenstock H, Ehrlich GE, Freyberg RH:Rheumatoid arthritis of the cricoarytenoid joint:A clinicopathologic study. Arthritis Rheum 6:48-62, 1963
PubMed
6) 大石公直:慢性関節リウマチによる輪状披裂関節の病変の臨床的ならびに病理組織学的研究. 日気食会報, 31:457-472, 1980
 
7) 野沢悟, 伊藤聡, 石川 肇ら:輪状披裂関節病変を認めたRAの2例. リウマチ科 14:519-525, 1995
 
8) 奥田恭章, 高杉 潔, 今井淳子ら:慢性関節リウマチにおける喉頭輪状披裂関節病変. リウマチ 32:245-251, 1992
 
9) 滝沢克巳, 青木大輔, 石井甲介ら:慢性関節リウマチによる輪状披裂関節障害.日気食会報 51:411-415, 2000
 
10) Ossof RH, Karlan MS, Sisson GA:Endoscopic laser arytenoidectomy. Lasers Surg Med 2:293-299, 1983
 
P.56 掲載の参考文献
1) 本郷一郎:結合織炎症候群. リウマチ病セミナーI (七川歡次監修), pp95-111, 大阪, 永井書店, 1990
 
2) 西岡淳一:Fibromyalgiaのレゾンデートル. リウマチ病セミナーV (七川歡次監修), pp69-77, 大阪, 永井書店, 1994
 
3) 浦野房二, 鈴木貞博:線維筋痛症候群の短期治療成績. 臨床リウマチ 10:259-265, 1998
 
4) 長岡章平, 大野美香子, 関口章子:当科における過去4年間に経験した線維筋痛症候群の臨床的検討. 臨床リウマチ 15:13-18, 2003
 
5) Wolfe F, Smythe HA, Yunus MB, et al:The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33:160-172, 1990
PubMed
6) Shichikawa K, Takenaka Y, Yukioka M:Polyenthesitis. Rheum Dis Clin North Am (Muhamad Asim Khan, MD, Frcp, ed), 18:203-213, 1992
 
7) 行岡正雄, 脇谷滋之, 七川歡次ら:結合織炎症侯群 (Fibromyalgia Syndrome) の検討. 臨床リウマチ 3:80-86, 1990
 
8) 行岡正雄, 速水泰彦, 七川歡次ら:99mTcの胸肋部への異常集積を伴ったFibromyalgia Syndromeの検討. 中部整災誌 36:479-480, 1993
 
9) 小島国利, 水谷一裕, 茂手木三男ら:胸肋鎖骨異常骨化症の臨床的検討. 整形・災害外科 29:1483-1490, 1986
 
10) 行岡正雄, 七川歡次, 久米田靖郎ら:99mTcで胸肋鎖骨部に異常集積を認めるFibromyalgia Syndromeの1例. 臨床リウマチ 13:144-150, 2001
 
11) 辻本正記, 谷仁孝, 喜多貞夫ら:SpondyloarthropathyにおけるAmorのClassification criteriaの検討. リウマチ病セミナーII (七川歡次監修), pp25-31, 大阪, 永井書店, 1991
 
12) Fitzcharles MA, Esdaile JM:The overdiagnosis of fibromyalgia syndrome. Am J Med 103:44-50, 1997
PubMed
13) 塩沢和子:甲状腺機能低下とリウマチ症状. リウマチ病セミナーX (七川歡次監修), pp61-83, 大阪, 永井書店, 1999
 
14) Hsu W, Patella SJ, Sigal LH:"Chronic Lyme Disease" as the incorrect diagnosis in patients with fibromyalgia. Arthritis Rheum 36:1493-1500, 1993
 
15) Dinerman H, Goldenberg DL, Felson DT:A prospective evaluation of 118 patients with the fibromyalgia syndrome:prevalence of raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J Rheumatol 13:368-373, 1986
PubMed
16) 行岡正確, 七川歡次, 今岡弘之ら:結合織炎症候群を伴った絞拒性神経障害. 日手会誌 9:151-154, 1992
 
17) 行岡正雄, 七川歡次, 今岡弘之ら:Fibromyalgiaを合併した胸郭出口症候群. 日手会誌 14:472-475, 1997
 
18) Yunus MB, Aldag JC:Restless legs syndrome and leg cramps in fibromyalgia syndrome:a controlled study. BMJ 312:1339, 1996
PubMed
19) Alvarez Lario B, Alonso Valdivielso JL, Alegre Lopez J, et al:Fibromyalgia syndrome:overnight falls in arterial oxygen saturation. Am J Med 101:54-60, 1996
PubMed
20) Magni G, Moreschi C, Rigatti-Luchini S, et al:Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain 56:289-297, 1994
PubMed
21) Hawley DJ, Wolfe F:Depression is not more common in rheumatoid arthritis:A 10-year longitudinal study of 6, 153 patients with rheumatic disease. J Rheumatol 20:2025-2031, 1993
 
22) Okifuji A, Turk DC, Sherman JJ:Evaluation of the relationship between depression and fibromyalgia syndrome:Why aren it all patients depressed? JRheumatol 27:212-219, 2000
PubMed
23) Arnold LM, Keck PE, Welge JA:Antidepressant treatment of fibromyalgia, A meta-analysis and review. Psychosomatics 41:104-113, 2000
PubMed
24) 行岡正雄, 小松原良雄:RAに合併した抑うつ状態とその診断・治療. リウマチ科 27:578-583, 2002
 
25) Branco J, Atalaia A, Paiva T:Sleep cycles and alpha-delta, sleep in fibromyalgia syndrome. J Reumatol 21:1113-1117, 1994
 
26) Moldofsky H, Scarisbrick P, England R, et al:Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 37:341-351, 1975
 
27) Moldofsky H, Scarisbrick P:Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 38:35-44, 1976
PubMed
28) Lentz MJ, Landis CA, Rothermel J, et al:Effects of selective slow wave sleep disruption musculoskeletal pain and fatigue in middle aged women. J Rheumatol 26:1586-1592, 1999
PubMed
29) Older SA, Battafarano DF, Danning CL, et al:The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects; correlations with insulin-like growth factor I. J Reumatol 25:1180-1186, 1998
 
30) Roizenbratt S, Tufik S, Goldenberg J, et al:Juvenile fibromyalgia; Clinical and polysomnographic aspects. J Reumatol 24:579-585, 1997
 
31) Whelton CL, Salit I, Moldofsky H:Sleep, epstein-barr virus infection, musculoskeltal pain, and depressive symptoms in chronic fatigue syndrome. J Rheumatol 19:939-943, 1992
 
32) Roizenblatt S, Moldofsky H, Benedito-Silva AA:Alpha sleep characteristics in fibromyalgia. Arthritis Rheum 44:222-230, 2001
PubMed
33) Moldofsky H and Warsh JJ:Plasma tryptophan and musculoskeletal pain in non-articular rheumatism. Pain 5:65-71, 1978
PubMed
34) 吉野良平:1-トリプトファン症候群 (好酸球増多-筋痛症候群). リウマチ病セミナ III (七川歡次監修), pp45-56, 大阪, 永井書店, 1991
 
35) 横田敏勝:線維筋痛症候群. 痛みのメカニズム:pp106-108, 南山堂, 1997
 
36) Russel IJ Neurochemical pathogenesis of fibromyalgia syndrome. J musculoskeletal Pain 4:61-92, 1996
 
37) Pillemer SR, Bradley LA, Crofford LJ, et al:The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 40:1928-1939, 1997
PubMed
38) Citera G, Arias MA, Maldonado-Cocco JA, et al:The effect of melatonin in patients with fibromyalgia:a pilot study. Clin Rheumatol 19:9-13, 2000
 
39) Poyhia R, Costa DD, Fitzcharles MA:Pain and pain relief in fibromyalgia patients followed for three years. Arthritis Care & Research 45:355-361, 2001
 
40) Hawley DJ, Wolfe F, Cathey MA:Pain, functional disability, and psycological status:A 12-month study of severity in fibromyalgia. J Rheumatol 15:1551-1556, 1998
 
41) Felson DT, Goldenberg DL:The natural history of fibromyalgia. Arthritis Rheum 29:1522-1526, 1986
PubMed
42) Ledingham J, Doherty S, Doherty M:Primary fibromyalgia syndrome:an outcome study. Br J Rheumatol 32:139-142, 1993
PubMed
43) Wolfe F, Anderson J, Harkness D, et al:Health status and disease severity in fibromyalgia:Result of a sixcenter longitudinal study. Arthritis Reum 40, 1571-1579, 1997
 
44) Granges G, Zilko P, Littlejohn GO:Fibromyalgia syndrome:Assessment of the severity of the condition 2 years after diagnosis. J Rheumatol 21, 523-529, 1994
PubMed
45) Russell IJ, Fletcher EM, Michalek JE, et al:Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alphazolam, a double-blind, placego-controlled study. Arthritis Rheum 34:552-560, 1991
PubMed
46) Clark S, Tindall E, Bennett RM:A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 12:980-983, 1985
PubMed
47) Goldenberg DL, Felson DT, Dinerman H:A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 29:1371-1377, 1986
PubMed
48) Jaeschke R, Adachi J, Guyatt G, et al:Clinical usefulness of amitriptyline in fibromyalgia; the results of 23 nof-1 randomized controlled trials. J Rheumatol 18:447-451, 1991
 
49) Anderberg UM, Marteinsdottir I, von Knorring L:Citalopram in patients with fibromyalgia:a randomized, double-blind, placebo-controlled study. European J Pain 4:27-35, 2000
 
50) Giordano N, Geraci S, Santacroce C, et al:Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome:A single-blind study. Current therapeutic Research 60:696-702, 1999
 
51) Wolfe F, Cathey MA, Hawley DJ:A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 23:255-259, 1994
PubMed
52) Goldenberg D, Mayskiy M, Mossey C, et al:A randomized, double-blind crossover traial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39:1852-1859, 1996
 
53) 井上康二:ブロモクリプチンとソマトメジンC. リウマチ病セミナーX (七川歡次監修), pp.219-225, 大阪, 永井書店, 1999
 
54) Bennett RM, Clark SC, Walczyk J:A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104:227-231, 1998
PubMed
55) Paiva ES, Deodhar A, Jones KD, et al:Impaired growth hormone secretion in fibromyalgia patients. Arthritis Rheum 46:1344-1350, 2002
PubMed
56) Spath M:Current experience with 5-HT3 receptor antagonists in fibromyalgia. Rheum Dis Clin N Am 28:319-328, 2002
 
57) Farber L, Stratz T, Bruckle W, et al:Efficacy and tolerabiliy of tropisetron in primary fibromyalgia; a highly selective and competitive 5HT3 receptor antagonist. the German Fibromyalgia Study Group. Scand J Rheumatol 29:49-54, 2000
 
58) Papadopoulos IA, Georgiou PE, Katsimbri PP, et al:Treatment of fibromyalgia with tropisetron, a 5-HT3 serotonin antagonist:a pilot study. Clin Rheumatol 19:68, 2000
 
59) 西岡真樹子, 松本美富士, 西岡久寿樹:FMS/CFS病態とノイロトロピンの有効性について, リウマチ 43:331, 2003
 
60) Burckhardt CS:Nonpharmacologic management strategies in fibromyalgia. Rheum Dis Clin North Am 28:291-304, 2002
PubMed
61) Shapiro CM, Bortz R, Mitchell D:Slow-wave sleep:A recovery period after exercize. Science 214:1253-1254, 1981
 
62) Harbar VJ, Sutton JR:Endorphins and exercise. Sports Med 1:154-171, 1984
 
63) McCain GA, Bell DA, Mai FM, et al:A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 31:1135-1141, 1988
PubMed
64) Burckhardt CS, Mannerkorpi K, Hedenberg L, et al:A randomized, controlled clinical trial of education and physical training for women with fibromyalgia. J Rheumatol 21:714-720, 1994
PubMed
65) Gowans SE, deHueck A, VOSS S, et al:Effect of a randomized, controlled trial of exercise on mood and physical function in individuals with fibromyalgia. Arthritis Care Res 45:519-529, 2001
 
66) Kim DJ, Sharon RC:Individualizing the exercise prescription for persons with fibromyalgia. Rheum Dis Clin North Am 28:419-436, 2002
 
67) Russell IJ:The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin North Am 28:329-342, 2002
PubMed
68) Mountz JM, Bradley LA, Modell JG, et al:Fibromyalgia in women, abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 38:926-938, 1995
PubMed
69) Gracely RH, Petzke F, Wolf JM, et al:Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46:1333-1343, 2002
PubMed
70) Staud R, Vierck CJ, Cannon RL, et al:Abnormal sensitization and temporal summation of second pain (windup) in patients with fibromyalgia sydrome. Pain 91:165-175, 2001
 
P.63 掲載の参考文献
1) Rimon R:Depression in rheumatoid arthritis. Ann Clin Res 6:171-175, 1974
PubMed
2) Creed F, Murphy S, Jayson MV:Measurement of psychiatric disorder in rheumatoid arthritis. J Psychosom Res 34:79-87, 1990
PubMed
3) Abdel-Nasser AM, Abd El-Azim S, Taal E, et al:Depression and depressive symptoms in rheumatoid arthritis patients:An analysis of their occurrence and determinants. Br J Rheum 37:391-397, 1998
 
4) 行岡正雄:慢性関節リウマチ患者と心理 (第:報) 慢性関節リウマチにみられた抑鬱傾向に関する研究. 第15回日本臨床リウマチ学会での報告
 
5) El-Miedany W, El Rasheed AH:Is anxiety a more common disorder than depression in rheumatoid arthritis? Joint Bone Spine 69:300-306, 2002
 
6) 大西英生:RA患者の情動反応とストレスホルモンおよびサイトカインとの関連. リウマチ科 23:374-380, 2000
 
7) Hawley DJ, Wolfe F:Anxiety and depression in patients with rheumatoid arthritis:A prospective study of 400 patients. J Rheumatol 15 (6):932-941, 1988
PubMed
8) 星 恵子, 高橋美恵子, 後藤恵子:リウマチ疾患とストレスマネージメント. 綜合臨牀 5:1104-1107, 2001
 
9) 野中藤吾, 丹彰 浩, 菊池 啓ら:慢性関節リウマチ患者の身体的障害がおよぼす心理面への影響. 臨床リウマチ 11:265-268, 1999
 
10) Zautra AJ, Smith BW:Depression and reactivity to stress in older women with rheumatoid arthritis and osteoarthritis. Psychosom Med 63:687-696, 2001
PubMed
11) Sharpe L, Sensky T, Allard S:The course of depression in recent onset rheumatoid arthritis. The predictive role of disability, illness perceptions, pain and coping. J Psychosom Res 51:713-719, 2001
PubMed
12) Evers AWM, Kraaimaat FW, Geenen R, et al:Determinants of psychological distress and its course in the first year after diagnosis in rheumatoid arthritis patients. J Behav Med 20:489-504, 1997
 
13) 黒田広生, 中尾一志, 出口静吾ら:心身医学からみたRA患者の特徴について. 臨床リウマチ 9:136-141, 1997
 
14) McFarlane AC, Kalucy RS, Brooks PM:Psychological predictors of disease course in rheumatoid arthritis. J Psychosom Res 31:757-764, 1987
PubMed
15) Wolfe F, Hawley DJ:The relationship between clinical activity and depression in rheumatoid arthritis. J Rheum 20 (12):2032-2037, 1993
PubMed
16) Stahl SM:Peptides and psychiatry, part3:Substance P and serendipity:Nobel psychotropics are a possibility. J Clin Psychiat 60:140-141, 1999
 
17) Kramer MS, Cutler N, Feighner J, et al:Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645, 1998
PubMed
18) Fifield J, Tennen H, Reisine S, et al:Depression and the long-term risk of pain, fatigue, and disability in patients with rheumatoid arthritis. Arthritis & Rheumatology 41:1851-1857, 1998
 
19) 芦原 睦, 山田恵美:リウマチ・膠原病治療薬服用者に抗うつ薬を併用するときの注意点. 臨床と薬物治療 20:845-849, 2001
 

燐・カルシウム代謝

P.70 掲載の参考文献
1) Rachow JW, Ryan LM, McCarty DJ, et al:Synovial fluid inorganic pyrophosphate concentration and nucleotide pyrophosphohydrolase activity in basic calcium phosphate deposition arthropathy and Milwaukee shoulder syndrome. Arthritis Rhem 31:408-413, 1988
 
2) Ho AM, Johnson MD, Kingsley DM:Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289:265-270, 2000.
PubMed
3) Sweet HO, Green MC:Progressive ankylosis, a new skeletal mutation in the mouse. J Hered 72:87-93, 1981.
PubMed
4) Hughes AE, McGibbson D, Woodward E, et al:Localization of a gene for chondrocalcinosis to chromosome 5p. Hum Mol Genet 4:1225-1228, 1995
 
5) Andrew LJ, Brancolini V, Serrano de la Penna L, et al. Refinement of the chromosome 5p locus for familial calcium pyrophosphate dihydrate deposition disease. Am J Hum Genet 64:136145, 1999.
 
6) Johnson M, Ho A, McGrath R, et al:Analysis of the ANK gene reveals a heterozygous missense mutation in a French family with calcium pyrophosphate deposition disease (CPPDD) [abstract]. Arthritis Rhem 44:S161, 2001.
 
7) Pendleton A, Jognston M, Ho A, et al:Aheterozygous mutation in the human ANK gene in a British family with adult onset chondrocalcinosis due to calcium pyrophosphate crystal deposition [abstract]. Arthritis Rhem 44:S101, 2001.
 
8) Peariso S, McGraph R, Bonavita G, et al:Characterization of sequence variants in ANK in familial calcium pyrophosphate deposition disease (CPPDD) [abstract]. Arthritis Rhem 44:S162, 2001.
 
9) Nurnberg P, Thiele H, Chandler H, et al:Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 28:37-41, 2001.
 
10) Reichenberger E, Tiziani V, Watanabe S, et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 68:1321-1326, 2001.
PubMed
P.79 掲載の参考文献
1) 杉本利嗣:Calcium-sensing receptor. リウマチ病セミナーX (七川歡次監修), pp242-251, 大阪, 永井書店, 1999
 
2) Al-Ghamdi SM, Cameron EC, Sutton RA:Magnesium deficiency:pathophysiologic and clinical overview. Am J Kid Dis 24:737-752, 1994
PubMed
3) Boskey AL, Posner AS:Effect of magnesium on lipoid-induced in vitro model for bone mineralization. Calcif Tissu Int 32:139-143, 1980
 
4) Bigi A, Foresti E, Gregorini E, et al:The role of magnesium on the structure of biological apatites. Calcif Tissue Int 50:439-444, 1992
 
5) Sojka JE:Magnesium supplementation and osteoporosis. Nutr Rev 53:71-80, 1995
PubMed
6) Creedon A, Flynn A, Cashman K:The effect of moderately and severely restricted dietary magnesium intakes on bone composition and bone metabolism. Br J Nutr 82:63-67, 1999
 
7) Boncimino K, McMahon DJ, Addesso V, et al:Magnesium deficiency and bone loss after cardiac transplantation. J Bone Miner Res 14:295-303, 1999
PubMed
8) Toba Y, Kajita Y, Masuyama R, et al:Dietary magnesium supplementation affects bone metabolism and dynamic strength of bone in ovariectomized rats. J Nutr 130:216-220, 2000
PubMed
9) New SA, Robins SP, Campbell MK, et al:Dietary influences on bone mass and bone metabolism:further evidence of a positive link between fruit and vegetable consumption and bone health? Am J Clin Nutr 71:142-151, 2000
 
10) 0kuma T:Magnesium and bone strength. Nutrition 17:579-680, 2001
 
11) Schaafsma A:Delay of natural bone loss by higher intakes of specific minerals and vitamins. Crit Rev Food Sci Nutr 41:225-249, 2001
PubMed
12) Brown EM, Gamba G, Riccardi D, et al:Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
PubMed
13) Shinki T, Jin CH, Nishimura A, et al:Parathyroid hormone inhibits 25-hydroxyvitamin D3-24-hydroxylase mRNA expression stimulated by 1a, 25-dihydroxyvitamin D3 in rat kidney but not in intestine. J Biol Chem 267:13757-13762, 1992
 
14) Yamamoto M, Kawanobe Y, Takahashi H, et al:Vitamin D deficiency and calcium transport in the rat. J Clin Invest 74:507-513, 1984
 
15) Sugimoto T, Fukase M, Tsutsumi M, et al:Impaired parathyroid hormone-stimulated adenosine 3', 5'-monophosphate release by isolated perfused bones obtained from vitamin D-deficient rats. Endocrinology 118:1808-1813, 1986
PubMed
16) Demay BM, Kiernan MS, DeLuca HF, et al:Sequences in the human parathyroid hormone gene that bind the 1, 25-dihydroxyvitamin D3 receptor and mediate transcriptional regression in response to 1, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 89:8097-8101, 1992
 
17) Kitanaka S, Takeyama K, Murayama A, et al:Inactivating mutations in the 25-hydroxyvitamin D3 1a-hydroxylase gene in patients with pseudovitamin D-deficient rickets. N Engl J Med 338:653-661, 1998
 
18) 0yama Y, Ozono K, Uchida M, et al:Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J Biol Chem 269:10545-10550, 1994
 
19) Dagnel JL, Mangels AR, Moser-Veillon PB:Magnesium homeostasis:conservation mechanism in lactating women consuming a controlled magnesium diet. Am J Clin Nutr 59:990-994, 1994
 
20) Liwsbona F, Alferez MJ, Barronuevo M, et al:Effects of type of dietary fat and cholecalciferol on magnesium absorption in rats with intestinal resection. Int J Vitam Nutr 64:135-143, 1994
 
21) 杉本利嗣:高カルシウム尿症リウマチ病セミナーX (七川歡次監修), pp97-104, 大阪, 永井書店, 2002
 
22) Simon DB, Lu Y, Choate KA, et al:Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285:103-106, 1999
PubMed
23) Brown EM:A cloned extracellular Ca sensing recptor:molecular mediator of the action of extracellular Ca on parathyroid and kidney cells? Kidney Int 40:1042-1046, 1996
 
24) DeRouffignac C:Renal magnesium handling and its hormonal control. Physiol Rev 74:305-322, 1994
 
25) Hebert SC:Extracellular calcium-sensing receptor:implications for calcium and magnesium handling in the kidney. Kidney int 50:2129-2139, 1996
PubMed
26) Wang W:Two types of K+ channel in TAL of rat kidney. Am J Physiol 267:F599-F605, 1994
PubMed
27) Wang W, Lu M, Balazy M, et al:Phospholipaqse A2 is involved in mediating the effect of extracellular Ca2+ on apical K+ channels in rat TAL. Am J Physiol 273:F421-F429, 1997
PubMed
28) Al-Ghamdi SM, Camneron EC, Sutton RA:Magnesium deficiency:pathophysiology and clinical overview. Am J Kid Dis 24:737-752, 1994
 
29) Iseri LT, French JH:Magnesium:Nature physiologic calcium blocker. Am Heart J 108:188193, 1984
 
30) Zofkova I, Kancheva RL:The relationship between magnesium and calciotropic hormones. Magnesium Res 8:77-84 1995
PubMed
31) Rude RK, Oldham SB, Singer FR:Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol 5:209-224, 1976
PubMed
32) Bianchetti MG, Bettinelli A, Casez JP, et al:Evidence for disturbed regulation ofcalciotropic hormone metabolism in Gitelman syndrome. J Clin Endocrinol Metab 80:224-228, 1995
PubMed
33) Nedler JL, Rude RK:Disorders of magnesium metabolism. Endocrinol Metab Clin North Am 24:623-641, 1995
 
34) Fatemi S, Ryzen E, Flores J, et al:Effect of experimental human magrlesium depletion on parathyroid hormone secretion and 1, 25-dihydroxyvitamin D metabolism. J Clin Endocrinol Metab 73:1067-1072, 1991
PubMed
35) Rude RK:Magnesium deficiency:a cause of heterogenous diseases in humans. J Bone Miner Res 13:749-758, 1998
PubMed
P.86 掲載の参考文献
1) 名和田新, 柳瀬敏彦, 蘆田健二ほか:加齢と副腎アンドロゲン. 最新医学 56:2402-11, 2001
Medical*Online
2) Mobbs CV:Dehydroepiandrosterone and aging. In:Mobbs CV, Hof PR, Eds. Functional endocrinology of aging (interdisciplinary topics in gerontology), 29. Basel:Karger P.217-27, 1998
 
3) Cormier C, Souberbielle J-C, Kahan A:DHEA in bone and joint diseases. Joint Bone Spine 68:588-94, 2001
PubMed
4) Roth GS, Lane MA, Ingram DK, et al:Biomarkers of caloric restriction may predict longevity in humans. Science 297:811, 2002
PubMed
5) Lane MA, Ingram DK, Ball SS, et al:Dehydroepiandrosterone sulfate:a biomarker of primate aging slowed by calorie restriction. J Clin Endocrinol Metab 82:2093-96, 1997
PubMed
6) Greendale GA, Edelstein S, Barrett-Connor E:Endogenous sex steroids and bone mineral density in older women and men:the Rancho Bernardo study. J Bone Miner Res 12:1833-43, 1997
 
7) Garnero P, Sornay-Rendu E, Claustrat B, et al:Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women:the OFELY study. J Bone Miner Res 15:1526-36, 2000
PubMed
8) Haden ST, Glowacki J, Hurwitz S, et al:Effects of age on serum dehydroepiandrosterone sulfate, IGF-I and IL-6 levels in women. Calcif Tissue Int 66:414-8, 2000
PubMed
9) Clarke BL, Ebeling PR, Jones JD, et al:Changes in quantitative bone histomorphometry in aging healthy men. J Clin Endocrinol Metab 81:2264-70, 1996
 
10) Fatayerji D, Eastell R. Age-related changes in bone turnover in men. J Bone Miner Res 14:1203-10, 1999
 
11) Kasperk CH, Wakley GK, Hierl T, et al:Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 12:464-71, 1997
PubMed
12) Martel C, Sourla A, Pelletier G, et al:Predominant androgenic component in the stimulatory effects of dehydroepiandrosterone on bone mineral density in the rat. J Endocrinol 157:433-42, 1998
 
13) Labrie F, Diamond P, Cusan L, et al:Effect of a 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82:3498-505, 1997
 
14) Villareal DT, Holloszy JO, Kohrt WM, et al:Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol 53:561-8, 2000
 
15) Baulieu E-E, Thomas G, Legrain S, et al:Dehydroepiandrosteone (DHEA), DHEA sulfate, and aging:contribution of the DHEAge study to a sociobiomedical issue. Proc Natl Acad Sci USA 97:4279-84, 2000
 
16) Gordon CM, Grace E, Emanss J, et al:Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. J Bone Miner Res 14:136-45, 1999
PubMed
17) Callies F, Fassnacht M, Van Vlijmen JC, et al:Dehydroepiandrosterone replacement in women with adrenal insufficiency:effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 86:1968-72, 2001
PubMed
P.94 掲載の参考文献
1) Barengolts El, Berman M, Kukreja SC, et al:Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 62:209-213, 1998
 
2) Nishizawa Y, Morii H:Osteoporosis and atherosclerosis in chronic renal failure. Osteoporosis Int 7:S188-192, 1997
PubMed
3) Hak AE, Pols HA, van Hemert AM, et al:Progression of aortic calcification is associated with metacarpal bone loss during menopause:a population-based longitudinal study. Arterioscler Thromb Vasc Biol 20:1926-1931, 2000
PubMed
4) Giachelli CM:Ectopic calcification:gathering hard facts about soft tissue mineralization. Am J Pathol 154:671-675, 1999
PubMed
5) Watson KE, Bostrom K, Ravindranath R, et al:TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 93:2106-2113, 1994
PubMed
6) Shioi A, Nishizawa Y, Jono S, et al:Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 15:2003-2009, 1995
PubMed
7) Jono S, Nishizawa Y, Shioi A, et al:Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17:1135-1142, 1997
PubMed
8) Parhami F, Morrow AD, Balucan J, et al:Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 17:680-687, 1997
PubMed
9) Proudfoot D, et al:Apoptosis regulates human vascular calcification In vitro:evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 87:1055-1062, 2000
PubMed
10) Proudfoot D, Skepper JN, Shanahan CM, et al:Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 18:379-388, 1998
PubMed
11) Luo G, Ducy P, McKee MD, et al:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81, 1997
PubMed
12) Zebboudj M, Imura M, Bostrom K, et al:Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 277:4388-4394, 2002
 
13) Braam LA, Dissel P, Gijsbers BL, et al:Assay for human matrix gla protein in serum:potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 20:1257-1261, 2000
PubMed
14) Farzaneh-Far A, Davics JD, Braam LA, et al:A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem 276:32466-32473, 2001
 
15) Herrmann SM, et al:Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 20:2386-2393, 2000
PubMed
16) 田中栄:オステオプロテジェリン. リウマチ病セミナーXIII (七川歡次監修), pp136-140, 大阪. 永井書 店, 2002
 
17) Dhore CR, Cleutjens JP, Lutgens E, et al:Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21:1998-2003, 2001
PubMed
18) Hofbauer LC, Khosla S, Dunstan CR, et al:The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12, 2000
PubMed
19) Bucay N, Sarosi I, Dunstan CR, et al:osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268, 1998
PubMed
20) Browner WS, Lui LY, Cummings SR:Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-367, 2001
PubMed
21) Jono S, Ikari Y, Shioi A, et al:Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192-1194, 2002
PubMed
22) Kuro-o M, Matsumura Y, Aizawa H, et al:Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51, 1997
PubMed
23) 重松 隆, 山本裕康, 横山啓太郎:腎不全におけるカルシウム代謝とその管理. 日本透析医学会誌 33:321-323, 2000
 
24) Levy RJ, Schoen FJ, Levy JT, et al:Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol 113:143-155, 1983
PubMed
25) Jono S, McKee MD, Murry CE, et al:Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-17, 2000
PubMed
26) Suzuki A, Palmer G, Bonjour JP, et al:Stimulation of sodium-dependent phosphate transport and signaling mechanisms induced by basic fibroblast growth factor in MC3T3-E1 osteoblast-like cells. J Bone Miner Res 15:95-102, 2000
 
27) Zhen X, Bonjour Jp, Caverzasio J:Platelet-derived growth factor stimulates sodium-dependent Pi transport in osteoblastic cells via phospholipase Cgamma and phosphatidylinositol 3'-kinase. J Bone Miner Res 12:36-44, 1997
PubMed
28) Palmer G, Guicheux J, Bonjour JP, et al:Transforming growth factor-beta stimulates inorganic phosphate transport and expression of the type III phosphate transporter Glvr-1 in chondrogenic ATDC5 cells. Endocrinology 141:2236-2243, 2000
PubMed
29) Kannel WB, Hjortland MC, McNamara PM, et al:Menopause and risk of cardiovascular disease:the Framingham study. Ann Intern Med 85:447-452, 1976
PubMed
30) Stampfer MJ, Colditz GA, Willett WC, et al:Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325:756-762, 1991
PubMed
31) Karas RH, Patterson BL, Mendelsohn ME:Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 89:1943-1950, 1994
PubMed
32) Koshiyama H, Nakamura Y, Tanaka S, et al:Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 85:2793-2796, 2001
 
33) Kramsch DM, Chan CT:The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ Res 42:562-571, 1978
PubMed
34) Mundy G, Garrett R, Harris S, et al:Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949, 1999
PubMed
35) Chung YS, Lee MD, Lee SK, et al:HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142, 2000
PubMed
36) Chan KA, Andrade SE, Boles M, et al:Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188, 2000
PubMed
37) Wang PS, Solomon DH, Mogun H, et al:HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. Jama 283:3211-3216, 2000
PubMed

検査法

P.100 掲載の参考文献
1) Waaler E:On the occurrence on a factor in human sera activating the specific agglutinations of sheep blood corpuscles. Acta Pathol Microbiol Scandinav 17:172, 1940
 
2) Rose HM, Regan C, Pearce E, et al:Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 68:1-6, 1948
 
3) Singer JM, Plotz CM:The latex fixation test I. Application to the serologic diagnosis of rheumatoid arthritis. Am J Med 21:888-892, 1956
 
4) 今福裕司, 吉田 浩:リウマトイド因子. リウマチ科 27:301-307, 2002
 
5) Nienhuis RLF, Mandena EA:A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum Dis 23:302-305, 1964
 
6) Hoet RM, Boerbooms AM, Arends M, et al:Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis:colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis:50:611-618, 1991
PubMed
7) Takahara H, Kusubata M, Tsuchida M, et al:Expression of peptidylarginine deiminase in the uterine epithelial cells of mouse is dependent on estrogen. J Biol Chem 5:267:520-525, 1992
PubMed
8) Schellekens GA, de Jong BA, van den Hoogen FH, et al:Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273-281, 1998
PubMed
9) Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al:The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro) filaggrin by deimination of arginine residues. J Immunol 162:585-594, 1999
PubMed
10) Sebbag M, Simon M, Vincent C, et al:The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies J Clin Invest 95:2672-2679, 1995
PubMed
11) Vincent C, de Keyser F, Masson-Bessiere C, et al:Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis 58:42-48, 1999
PubMed
12) Vincent C, Simon M, Sebbag M, et al:Immunoblotting detection of autoantibodies to human epidermis filaggrin:a new diagnostic test for rheumatoid arthritis. J Rheumatol 25:838-846, 1998
PubMed
13) Simon M, Girbal E, Sebbag M, et al:The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 92:1387-1393, 1993
PubMed
14) 斉藤潤:慢性関節リウマチの生物学的マーカー. リウマチ病セミナーVIII (七川歡次監修), pp148-155, 大阪, 永井書店, 1996
 
15) Masson-Bessiere C, Sebbag M, Durieux JJ, et al:In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 119:544-552, 2000
PubMed
16) Kurki P, Aho K, Palosuo T, et al:Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum 35:914-917, 1992
PubMed
17) Paimela L, Gripenberg M, Kurki P, et al:Antikeratin antibodies:diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 51:743-746, 1992
PubMed
18) Bas S, Perneger TV, Seitz M, et al:Diagnostic tests for rheumatoid arthritis:comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 41:809-814, 2002
PubMed
19) Paimela L, Palosuo T, Aho K, et al:Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis 60:32-35, 2001
PubMed
20) Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al:The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin. J Immunol 166:4177-7184, 2001
PubMed
21) Reparon-Schuijt CC, van Esch WJ, van Kooten C, et al:Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 44:41-47, 2001
 
22) Schellekens GA, Visser H, de Jong BA, et al:The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155-163, 2000
PubMed
23) Bizzaro N, Mazzanti G, Tonutti E, et al:Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47:1089-1093, 2001
PubMed
24) Baeten D, Peene I, Union A, et al:Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium:relevance to antifilaggrin autoantibodies. Arthritis Rheum 44:2255-2262, 2001
PubMed
25) van Jaarsveld CH, ter Borg EJ, Jacobs JW, et al:The prognostic value of the antiperinuclear factor, anti-citrtlllinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 17:689-697, 1999
PubMed
26) Goldbach-Mansky R, Lee J, McCoy A, et al:Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2:236-243, 2000
PubMed
27) Kroot EJ, de Jong BA, van Leeuwen MA, et al:The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831-1835, 2000
PubMed
28) Visser H, le Cessie S, Vos K, et al:How to diagnose rheumatoid arthritis early:a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357-365, 2002
 
29) Union A, Meheus L, Humbel RL, et al:Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 46:1185-1195, 2002
PubMed

生物学的反応

P.108 掲載の参考文献
1) Prince CW, Oosawa T, Butler WT, et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Bio Chem 262:2900-7, 1987
 
2) Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell binding sequence. Proc Natl Acad Sci USA 83:8819-23, 1986
PubMed
3) Denhardt DT, Guo X. Osteopontin:a protein with diverse functions. FASEB J 7:1475-82, 1993
PubMed
4) Bosky AL, Maresca M, Ullrich W, et al. Osteopontin-hydroxyapatite interactions in vitro:Inhibition of hydroxyapatite formation and growth in a gelatin gel. Bone Miner 22:147-59, 1993
 
5) Hunter GK, Hauschka PV, Poole AR, et al. Nucleation and inhibition of hydrooxyapatite formation by mineralized tissue protein. Biochem J 317:59-64, 1996
 
6) Ishijima M, Rittling SR, Yamashita T, et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 193:399-404, 2001
 
7) Ross FP, Chappel J, Alvarez JI, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin avB3 potentiate bone resorption. J Biol Chem 268:9901-7, 1993
 
8) Miyauchi A, Alvarez JI, Greenfield EM, et al. Recognition of osteopontin and related peptides by an avB3. J Biol Chem 266:20369-74, 1991
 
9) Yoshitake H, Rittling SR, Denhardt DT, et al. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 96:8156-60, 1999
PubMed
10) Ohshima S, Kobayashi H, Yamaguchi N, et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis of collagen-induced arthritis. Arthritis Rheum 46:1094-1101, 2002
 
11) Yumoto K, Ishijima M, Rittling SR, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody induced arthritis in mice. Proc Natl Acad Sci USA 99:4556-61, 2002
PubMed
12) Ohshima S, Yamaguchi N, Nishioka K, et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 29:2061-7, 2002
PubMed
13) Petrow PK, Hummel KM, Schedel J, et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis. Arthritis Rheum 43:1597-605, 2000
PubMed
14) Yamamoto N, Sakai F, Kon S, et al. Essential role of the criptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 112:181-8, 2003
 
15) Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin):an early component of type-1 (cellmediated) immunity. Science 287:860-4, 2000
PubMed
16) Jansson M, Panoutsakopoulou V, Baker J, et al. Cutting edge:Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-defiecient mice. J Immunol 168:2096-9, 2002
 
17) Chabas D, Baranzini SE, Mitchell, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-5, 2001
PubMed
18) Singh RP, Patarca R, Schwartz J, et al. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effects upon macrphages in vivo. J Exp Med 171:1931-42, 1990
 
19) Giachelli CM, Lombardi D, Johnson RJ, et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 152:353-8, 1998
PubMed
20) Lampe MA, Patarca R, Iregui MV, et al. Polyclonal B cell activation by Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol 147:2902-6, 1991
PubMed
21) Liaw L, Almeida M, Hart CE, et al. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Cir Res 74:214-24, 1994
 
22) O'Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Throm 14:1648-56, 1994
 
23) Chiba S, Okamoto H, Kon S, et al. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 16:111-7, 2002
PubMed
24) Fitzpatrick LA, Severson A, Edwards WD, et al. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 94:1597-604, 1994
PubMed
25) Williams EB, Halpert I, Wickline S, et al. Osteopontin increased in the heritable cardiomyopathy of Syrian hamsters. Circulation 92:705-9, 1995
PubMed
26) Worcester EM, Blumenthal SS, Beshensky AM, et al. The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7:1029-36, 1992
PubMed
27) Hwang SM, Lopez CA, Heck DE, et al. Osteopontin inhibits induction of nitric oxide synthetase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 269:711-5, 1994
PubMed
28) Pichler R, Giachelli CM, Lombardi D, et al. Tubulointerstitial disease in glomerulonepfritis:Potential role of osteopontin. 144:915-26, 1994
PubMed
29) Pichler R, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy:Roles of angiotensin II and osteopontin. J Am Soc Mephrol 6:1186-96, 1995
PubMed
30) Lan HY, Yu XQ, Yang N, et al. De novo glomerular osteopontin expression in rat crescentic glomerulonephritis. Kidney Int 53:136-45, 1998
PubMed
31) Wang X, Louden C, Yue TL, et al. Delayed expression of osteopontin after focal stroke in the rat. J Nerusci 18:2075-83, 1998
 
32) 0'Regan A, Berman JS. Osteopontin:a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 81:373-90, 2000
 
33) Nau GJ, Guifoile P, Chupp GL, et al. A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc Natl Acad Sci USA 94:6414-9, 1997
 
34) Chiba S, Rashid MM, Okamoto H, et al. The role of osteopontin in the development of granulomatous lesions in lung. Microbiol Immunol 44:319-32, 2000
PubMed
35) O'Regan AW, Hayden JM, Body S, et al. Abnormal pulmonary granuloma formation in osteopontin-deficient mice. Am J Respir Crit Care Med 164:2243-7, 2001
PubMed
36) Senger DR, Perruzzi CA, Papadopoulous A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-300, 1989
 
37) Brown LF, Papadopoulous-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 146:95-100, 1994
 
38) Yeatman TJ, Chambers AF. Osteopontin and colon cancer progression. Clin Exp Metastasis 20:85-90, 2003
PubMed
39) Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287:1671-9, 2002
PubMed
40) Chambers AF, Wilson SM, Kerlvliet N, et al. Osteopontin expression in lung cancer. Lung cancer 15:311-23, 1996
 
41) Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 289:1508-14, 2000
PubMed
42) Crippes BA, Engelman VW, Settle SL, et al. Antibody to B3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology 137:918-24, 1996
 
P.118 掲載の参考文献
1) Mundy GR:Metastasis to bone:causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593, 2002
PubMed
2) Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW:Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944-949, 1995
 
3) Ikeda T, Lioubin MN, Marquardt H:Human transforming growth factor type beta 2:production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry 26:2406-2410, 1987
PubMed
4) Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS:Prostate carcinoma skeletal metastases:cross-talk between tumor and bone. Cancer Metastasis Rev. 20:333-349, 2001
PubMed
5) Izbicka E, Dunstan C, Esparza J, Jacobs C, Sabatini M, Mundy GR:Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Cancer Res. 56:633-636, 1996
PubMed
6) Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA:Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54:2372-2377, 1994
PubMed
7) Cramer SD, Chen Z, Peehl DM:Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain:inactivation of PTHrP-stimtllated cAMP accumulation in mouse osteoblasts. J Urol. 156:526-531, 1996
PubMed
8) Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48:317-325, 1996
PubMed
9) Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate. 47:212-221, 2001
PubMed

治療と副作用

P.126 掲載の参考文献
1) Maetzel A:The callenges of estimating the national costs of osteoarthritis:Are we making progress. J Rheumatol 20:1181, 2002
 
2) Messier SP, Glasser JL, Ettinger WH, et al:Declines in strength and balance in older adults with chronic knee pain:A 30 month longitudinal, observational study. Arthrits Rheum 47:141-148, 2002
 
3) Hochberg MC, Altman RD, Brandt KD:Guidelines for the medical management of osteoarthritia:Part II, Osteoarthris of the knee. Arthritis Rheum 38:1541-1546, 1995
 
4) Branddt KD:The importance of nonpharmacologic approaches in management of osteoarthritis. Amer J Med 105:39-43, 1998
 
5) Ramsey SD, Spencer AC, Toopolski TD, et al:Use for alternative therapy by older adults with osteoarthritis. Arthritis Care & Reseach 45:222-227, 2001
 
6) Pendleton A, Arden N, Doogados M, et al:EURAL recommendations for the management of knee osteoarthritis:Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 59:8936-944, 2000
 
7) Fransen M, McConnell S, Bell M:Therapeutic exercise for people with osteoarthritis of the hip or knee:A systematic review. J Rheumatol 29:1737-1743, 2002
 
8) van Barr ME, Assendelft WJ, Dekker J, et al:Effectiveness of exercise in patients with osteoarthritis of the hip or knee. Arthritis Rheum 42:1361-1369, 1999
PubMed
9) van Barr ME, Dekker E, Ostendrof RAB, et al:The effectiveness of exercise in patients with osteoarthritis of hip or knee:Arandornized clinical trial. J Rheumatol 25:2432-2439, 1998
PubMed
10) Ettinger WH, Burns R, Messier SP, et al:A randomized trial comparing aerobic exercise and resistive exercise with a health education program in older adults with knee osteoarthritis. JAMA 277:25-31, 1997
PubMed
11) Boerjesson M, Robertson E, Weidenhielm L, et al:Physiotherapy in knee osteoarthritis:Effect on pain and walking. Physioththrapy Res Int 1:84-97, 1996
 
12) Kovar PA, Allegrant JP, MacKenjie R, et al:Supervised fittness walking in patients with osteoarthritis of the knee. Ann Intern Med 1156:529, 1992
 
13) Shilke JM, Johuson GO, Housh TJ, et al:Effect of musle strength training on the functional status of patients with osteoarthritis of the knee. Nurs Res 45:68-72, 1996
 
14) Bautch JC, Malone DG, Vailas AC:Effects of exercise on knee joints with osteoarthritis:A pilot study of biological markers. Arthritis Care Res 10:48-55, 1997
PubMed
15) Jan MH, Lai S:The effects of physioltherapy on osteoarthritic knee of females. J Formos Med Assoc 90:1008-1013, 1991
 
16) Deyle GD, Henderson NE, Matchel RL, et al:Effectiveness of manual therapy and exercise on osteoarthritis of the knee:A randomized, controlled trial. Ann Intern Med 132:173-181, 2000
 
17) Minor MA, Hewett JE, Webel OR, et al:Efficacy of physical conditioning exercise in patients with rheumatoid arthritis and osteoarthritis. Arhthritis Rheum 32:1396-1405, 1989
 
18) Kovar RA, Allegrant JP, MacKenzie CR, et al:Supervized fittness walking in patients with osteoarthritis of the knee. Ann Intern Med 116:527-534, 1992
 
19) Sullivan T, Nlegrant JP, Peterson MG, et al:One-year folowup of patients with osteoarthritis of the knee who participated in a program of supervised fittness walking and supportive patient education. Arthritis Care Res 11:128-133, 1998
 
20) Peloquin L, Paavo G, Gaathier P, et al:Effect of a mass-training exercise program in persons with osteoarthritis of the knee:A randomized controlled trial. J Clin Rheumatol 5:126-136, 1999
 
21) Mangione KK, McCullyK, Glovioak A, et al:The effect of high density and low-intensity cycling ergometry in older adults with knee osteoarthritis. J Gerontlol A Biol Sci Med Sci 54:M184-190, 1999
 
22) Westby MD, Henderson NE, Matekel RL, et al:Effectiveness of manual therapy and exercise on osteoarthritis of the knee:A randomized, controlled trial. Ann Intern Med 132:173-181, 2000
 
23) 戸田佳孝, 黒澤 尚, 吉永勝則ら:変形性膝関節症に対する運動療法. 日本リウマチ・関節外科学会雑誌 20 (supple):95-97, 2002
 
P.136 掲載の参考文献
1) Valchanou VD, Michailov P:High energy shock waves in the treatment of delayed and nonunion of fractures. Int Orthop 15:181-184, 1991
PubMed
2) Rompe JD, Hope C, Kullmer K, et al:Analgesic effect of extracorporeal shock-wave therapy on chronic tennis elbow. J Bone Joint Surg Br 78:233-237, 1996
PubMed
3) Rompe JD, Hopf C, Nafe B, et al:Low-energy extracorporeal shock wave therapy for painful heel:a prospective controlled single-blind study. Arch Orthop Trauma Surg 115:75-79, 1996
 
4) Loew M, Jurgowski W, Mau HC, et al:Treatment of calcifying tendinitis of rotator cuff by extracorporeal shock waves:a preliminary report. Journal of Shoulder & Elbow Surgery 4:101-106, 1995
PubMed
5) Ogden JA, Alvarez R, Levitt R, et al:Shock wave therapy for chronic proximal plantar fasciitis. Clin Orthop 387:47-59, 2001
PubMed
6) 西須 孝, 高橋謙二, 和田佑一ら:骨関節近傍の疾痛性疾患に対する低エネルギー体外衝撃波療法の治療 成績. 骨・関節・靭帯 12:1157-1170, 1999
 
7) 西須 孝, 高橋謙二, 藤田耕司ら:石灰沈着性腱板炎慢性例に対する衝撃波療法の治療成績. 肩関節 23:293-296, 1999
 
8) Delius M, Enders G, Heine G, et al:Biological effects of shock waves:lung hemorrhage by shock waves in dogs-pressure dependence. Ultrasound in Medicine & Biology 13:61-67, 1987
PubMed
9) 西須 孝, 守屋秀繁, 後藤澄雄ら:体外衝撃波による長管骨過成長の誘導と骨端線閉鎖-成長期家兎大腿骨における動物実験-. 骨・関節・靭帯 8:371-380, 1995
 
10) 西須 孝, 亀ケ谷真琴, 篠原裕治ら:体外衝撃波の骨関節発育に及ぼす影響. 日本小児整形外科学会雑誌 6:123-127, 1996
Medical*Online
11) Saisu T, Goto S, Wada Y, et al:Irradiation of the extracorporeal shock wave to the immature long bone causes overgrowth and local increase in bone mineral content. Trans Orthop Res Soc 24:s34, 1999
 
12) 西須 孝, 高橋謙二, 三橋 繁ら:小児長管骨骨幹部に対する体外衝撃波の骨塩量増加作用-幼若家兎を用いた動物実験からの考察-. 日本小児整形外科学会雑誌 9:152-157, 2000
Medical*Online
13) Yeaman LD, Jerome CP, McCullough DL:Effect of shock waves on the structure and growth of the immature rat epiphysis. J Urol 141:670-674, 1989
PubMed
14) 西須 孝, 高橋謙二, 三橋 繁ら:寛骨臼に対する体外衝撃波の作用-家兎を用いた実験的研究-. 臨床整形外科 34:1103-1109, 1999
 
15) Saisu T, Takahashi K, Mitsuhashi S, et al:Acetabular augmentation induced by extracorporeal shock waves in rabbits. Trans Orthop Res Soc 25:s519, 2000
 
16) Takahashi K, Saisu T, Wada Y, et al:Gene expression of extracelluler matrix proteins in shockwaves-induced osteogenesis in rats. Trans Orthop Res Soc 26:s532, 2001
 
17) 三橋 繁, 西須 孝, 高橋謙二:体外衝撃波を用いた新しい脊髄損傷モデルの作製. 日本神経救急研究会雑誌 13:50-53, 2000
 
18) Ohtori S, Inoue G, Mannoji C, et al:Shock wave application to rat skin induces degeneration and reinnervation of sensory nerve fibres. Neuroscience Letters 315:57-60, 2001
PubMed
19) Ikeda K, Tomita K, Takayama K:Application of extracorporeal shock wave on bone:preliminary report. J Trauma 47:946-950, 1999
 
20) Rompe JD, Kirkpatrick CJ, Kullmer K, et al:Dose-related effects of shock waves on rabbit tendo Achillis. A sonographic and histological study. J Bone Joint Surg Br 80:546-552, 1998
PubMed
21) Maier M, Saisu T, Beckmann J, et al:Impaired tensile strength after shock-wave application in an animal model of tendon calcification. Ultrasound Med Biol 27:665-671, 2001
 
22) 高橋憲正, 西須 孝, 高橋謙二ら:プロサッカー選手の難治性踵骨痛症候群に対する低エネルギー体外衝撃波療法. 日本臨床スポーツ医学会誌 11:71-75, 2003
Medical*Online
23) 小玉哲也, 永易伸生, 高橋和喜:水中衝撃波とゼラチンに付着した気泡との相互干渉. 平成&年度衝撃波シンポジウム講演論文集 (衝撃波シンポジウム運営委員会・宇宙科学研究所・東北大学流体科学研究所編), pp553-556, 横浜市, 衝撃波シンポジウム運営委員会・宇宙科学研究所・東北大学流体科学研究所発刊, 1995
 
24) Deam RK, Scott DA:Neurological damage resulting from extracorporeal shock wave lithotripsy when air is used to locate the epidural space. Anaesth Intens Care 21:455-457, 1993
 
P.149 掲載の参考文献
1) Lund University Consensus Meeting Co-sponsered by WHO:The bone and joint decade 2000-2010. Acta Orthop Scand:69 (Supple 281), 1998
 
2) Woolf AD, Shichikawa K, Ed.:International conference for bone and joint decade 2000-2010. J Rheumatol; 30 (Suppl 67), 2002
 
3) The international conference on health promotion and disability prevention for individuals and populations with rheumatic diseases:evidence for exercise and physical activity. St Louis, Missouri, USA, 2002,
 
4) Brady TJ, Kruger J, Helmick CG, et al.:Intervention programs for arthritis and rheumatic diseases. Health Educ Behav 30:44-63, 2003
PubMed
5) Bischoff HA, Roos EM:Effectiveness and safety of strengthening, aerobic, and coordination exercises for patients with osteoarthritis. Curr Opin Rheumatol 15:141-4, 2003
PubMed
6) Miyaguchi M, Kobayashi A, Kadoya Y, et al. Biochemical change in joint fluid after isometric quadriceps exercise for patients with osteoarthritis of the knee. Osteoarthritis Cartilage 11:548, 2003
 
7) Song R, Lee EO, Lam P, et al.:Effects of tai chi exercise on pain, balance, muscle strength, and perceived difficulties in physical functioning in older women with osteoarthritis:a randomized clinical trial. J Rheumatol 30:2039-44, 2003
PubMed
8) Hurley BF, Roth SM:Strength training in the elderly:effect on risk factors for age-ralated diseases. Sports Med 30:249-68, 2000
 
9) Resnick B:Managing arthritis with exercise. Geriatr Nurs 22:143-50, 2001
PubMed
10) Carter ND, Khan KM, McKay HA, et al.:Community-based exercise program reduces risk factors for falls in 65-to 75-year-old women with osteoarhtritis:randomized controlled trial. CMAJ 167:997-1004, 2002
 
11) Messier SP, Glasser JL, Ettinger WH, et al.:Declines in strength and balance in older adults with chronic knee pain:a 30-month longitudinal, observational study. Arthritis Rheum 47:141-8, 2002
 
12) Seguin R, Nelson ME:The benefits of strength training for older adults. Am J Prev Med 25 (Suppl 2):141-9, 200314
 
13) 西林保朗:厚生科学研究で明らかになったわが国の関節リウマチ患者の実態. 関節外科 22 (10月増刊号):130-5, 2003
 
14) Wilske KR, Healey LA:Remodelling the pyramid-a concept whose time has come. J Rheumatol 16:565-7, 1989
 
15) 日本リウマチ友の会編:'95リウマチ白書. 流178号, 東京, 身体障害者団体定期刊行物協会, 1995.
 
16) 日本リウマチ友の会編:2000年リウマチ白書. 流207号, 東京, 身体障害者団体定期刊行物協会, 2000.
 
17) American College of Rheumatology Subcommittee on Rheumatoid Arthritis:Guideline for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 46:328-46, 2002
PubMed
18) 橋本明:慢性関節リウマチのプールによるリハビリテーションの実際. リウマチ科 10:365-76, 1993
 
19) 西林保朗, 阿部修治, 八木範彦, 他:慢性関節リウマチに対する運動療法. 整形・災害外科 43:539-49, 2000
 
20) 椎野泰明:関節リウマチの運動療法第2版. 東京医歯薬出版, 2003
 
21) Roddy E, Doherty M:Guidelines for management of osteoarthritis published by the American College of Rheumatology and European League Against Rheumatism:why are they so different Rheum Dis Clin N Am 29:717-731, 2003
 
22) 介護予防・自立支援・パワーリハビリテーション研究会編. パワーリハビリテーシン No.1. 東京, 医歯薬出 版, 2002
 
23) 北潔, 藤野圭司, 那須耀夫他:整形外科的虚弱高齢者に対する運動療法の効果. 中部整災誌, 2003 (投稿中)
 
24) 井原秀俊:関節トレーニング. 改訂第2版-神経運動器協調訓練-. 東京, 協同医書出社, 1998
 
25) Ellenbecker TS, Davies GJ (山本利春, 中村千秋監訳). CKCエクササイズ. 東京, ナップ2003
 
26) 小林晴美, 八木範彦, 阿部修治, 他:慢性関節リウマチ患者における全身持久力訓練. 日本RAのリハビリ 研究会 13:31-3, 1998
 
27) 前田晃:リハビリはリウマチ病の治療にどれだけ役立つか? リウマチ病セミナーIII (七川歡次監) 230-7, 大阪, 永井書店, 1992
 
28) Haralson K:Physical therapy and arthritis. Arthritis Care and Research 3:173-7, 1990
 
29) 橋本明, 佐藤元, 近藤啓文, 他:AIMS2改訂日本語版調査票を用いた多施設共同のRA患者QOLの実態調査成績-記述統計報告並びにQOLに影響を及ぼす諸因子の解析. 平成6年度厚生省リウマチ調査研究事業 研究報告書:188-94, 1995
 
30) 橋本明, 佐藤元, 西林保朗, 他:RA患者のQOL:AIMS2改訂日本語版調査書を用いた多施設共同調査成績-1. 肢体不自由に関与する諸因子の解析-. リウマチ 41:9-24, 2001
 
31) アメリカ関節炎財団編 ([日本語版]日本リウマチ学会編):リウマチ性疾患患者のリハビリテーション. リウマチ入門. 第11版, 549-56, 東京, 萬有製薬, 1999
 
32) 日本リウマチ財団編:リハビリテーション. リウマチ基本テキスト. 東京日本リウマチ財団, 558-73, 2002
 
33) Bearne LM, Scott DL, Hurley MV:Exercise can reserve quadriceps sensorimotor dysfunction that is associated with rheumatoid arthritis without axcerbating disease activity. Rheumatology 41:157-66, 2002
 
34) 西林保朗, 久保仁志, 大森裕, 他:慢性関節リウマチ患者の在宅医療とリハビリテーション. MB Med Reha 6:79-89, 2001
 
35) De Jong Z, Munneke M, Zwinderman AH, et al.:Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 48:2393-5, 2003
 
36) Munneke M, De Jong Z, Zwinderman AH, et al.:Adherence and satisfaction of rheumatoid arthritis patients with a long-term intensive dynamic exercise program (RAPIT program). Arthritis Rheum 49:665-72, 2003
PubMed
37) Gyurcsik NC, Estabrooks PA, Frahm-Templar MJ:Exercise-related goals and self-efficacy as correlates of aquatic exercise in individuals with arthritis. Arthritis Rheum 49:306-13, 2000
 
38) Van den Ende CH, Breedveld FC, Le Cessie S, et al.:Effect of intensive exercise of patients with active rheumatoid arthritis:a randomized clinical trial. Ann Rheum Dis 59:615-21, 2000
PubMed
39) Lineker SC, Bell MJ, Wilkins AL, et al.:Improvements following short term home based physical therapy are maintained at one year in people with moderate to severe rheumatoid arthritis. J Rheumatol 28:165-8, 2001
PubMed
40) Hakkinen A, Sokka T, Koteniemi A, et al.:A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 44:515-522, 2001
 
41) 西林保朗:リウマチのエクササイズ. RA&セラピー64-12, 2000
 
42) 西林保朗:靱帯のhyperlaxityと過度運動性症候群. リウマチ病セミナーX (七川歡次監) 114-32, 大阪, 永井書店, 1999
 
43) 西林保朗:リウマチ性疾患の四肢痛. リウマチ科 27 (Suppl 1):151-61, 2002
 
44) 西林保朗:変形性膝関節症の痛みは何処のもの? 講演集-近畿リウマチ病研究会-(七川歡次, 志水正敏 監) 39-45, 堺, 近畿リウマチ病研究会, 2002
 
P.159 掲載の参考文献
1) Whitehead S, Clemenson G, Browse NL:The assessment of calf pump function by isotope plethysmography. Brit J Surg 70:675-679, 1983
 
2) Sumner DS:Hemodynamics and pathophysiology of venous disease. In Vascular Surgery (Rutherford RB ed. 3rd ed) WB Saunders, Philaderlphia, 1483-1504, 1989
 
3) Norman LB, Kevin GB, Michael LT:Diseases of Veins. Edward Arnold, London, pp151-168, 1988
 
4) 平井正文, 小谷野憲, 阪日周吉:臨床静脈学, 141-153, 東京, 中山書店, 1993
 
5) 清水康廣, 杉山悟, 松森秀之:試作ストリッピングワイヤーによる選択的ストリッピング法の検討, 日血外会誌 9:649-653, 1999
 
6) Hauer G:Die endoscopische subfaziale der perforansvenenvorlaufige mitteilung. VASA, 14:59-61, 1985
 
7) 岩井武尚, 上山武史, 折井正博ら:下肢静脈瘤硬化療法の実際. 第1版, 医学書院, 東京, 1-6, 1997
 
8) O'Brien BM, Sykes PJ, Threlfall GN, et al:Microlymphaticovenous anastomoses for obstructive lymphedema. Plast Reconst Surg 60:197-210, 1977
 
9) 八杉巧, 大西克幸, 山下広高ら:下肢リンパ浮腫に対するリンパ管静脈吻合術. 静脈学 14:25-30, 2003
 
10) 星野俊一, 佐戸川弘之:深部静脈血栓症 本邦における静脈疾患に関するSurvey. 静脈学 8:307-311, 1997
 
11) 中野赴, 中村真潮, 藤岡博文:静脈血栓症と肺塞栓症. 静脈学 8:211-228, 1997
 
12) Gore I, Hirst AE, Tanaka K:Myocardial infarction and thrombosis. Arch Intern Med 113:323-330, 1964
PubMed
13) 藤岡博文, 中村真潮, 中野赴:急性肺血栓塞栓症. 日本集中治療医学会雑誌, 3:1-8, 1996
 
14) Sasahara AA, Sharma GV, Barsamian EM et al:Pulmonary thromboembolism, diagnosis and treatment. JAMA 249:2945-2950, 1983
PubMed
15) 中村陽一, 由谷親夫, 今北正美ら:肺梗塞発生に至る肺静脈血栓症および肺血栓塞栓症の病理組織学的研究. 静脈学 7:17-22, 1996
 
16) 岡部功:術後深部静脈血栓症に関する研究-発症頻度と危険因子について. 日外会誌 81:214-225, 1980
 
17) 松本興治, 広瀬 一, 林勝知:術後深部静脈血栓症に関する研究. 静脈学 5:163-170, 1994
 
18) 山田典一, 中村真潮, 中野赳ら:肺血栓塞栓症の原因としての下肢深部静脈血栓症の診断-下肢静脈造影法と静脈エコー法との比較-静脈学 7:23-27, 1996
 
19) 栗山喬之:総合研究報告. 厚生省特定疾患呼吸器系疾患調査研究班. 呼吸不全調査研究班. 平成10年度研究報告書. 1-16, 1999
 
20) Sreeram N, Cheriex EC, Smeets JLRM et al:Value of the 12-lead electrocardiogram at hospital admission in the diagnosis of pulmonary embolism. Am J Cardiol 73:298-303, 1994
 
21) Cheriex EC, Sreeram N, Eussen YFJM et al:Distinguishing between acute and subacute massive pulmonary embolism by conventional and Doppler echocardiography. Br Heart J 72:52-57, 1994
 
22) Kasper W et al:Distinguishing between acute and subacute massive pulmonary embolism by conventional and Doppler echocardiography. Br Heart J 70:352-356, 1993
PubMed
23) 山田典一他:下肢深部静脈血栓症に対する超音波検査の有用性について. 心臓 27:331-336, 1995
Medical*Online
24) 井上芳徳他:ドプラ法による血流評価. 日本臨牀 57:1537-1541, 1999
Medical*Online
25) Fraser DG, Moddy AR, Morgan PS et al:Diagnosis of lower-limb deep venous thrombosis:a prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med 15; 136:89-98, 2002
 
26) 中村 真潮, 山田典一, 佐久間聖仁ら:わが国における急性肺血栓塞栓症の治療の現状とその評価. 静脈学 13:335-341, 2002
 
27) 坂本滋, 松原純一, 四方裕夫他:急性肺血栓塞栓症の検討. 静脈学 13:343-350, 2002
 
28) Yasuda K, Ayabe H, Ide H, et al:Thoracic and Cardiovascular Surgery in Japan during 2000. Annual Report by Japanese Association for Thoracic Surgery Committee of Science. JATS 50:398-412, 2002
 
29) 平井正文, 岩井武尚, 星野俊一:弾力性ストッキング. 弾力性ストッキングコンダクター 静脈疾患患者さんへの適切なアドバイスのために. pp 31-45, 東京, へるす出版, 2000
 
30) 平井正文:静脈疾患における圧迫療法. 静脈学 13:253-259, 2002
 
31) Clagett GP et al:Prevention of venous Thromboembolism. CHEST, 108:312s-334s, 1995
PubMed
32) 藤田 悟他:下肢人工関節置換術後におこる深部静脈栓症の発生頻度. 臨整外 31:101-1005, 1996
 
33) 平井正文:深部静脈血栓症・肺塞栓症予防における弾力ストッキング, 間欠的空気圧迫法の応用法. 静脈学 14:49-62, 2003
 
34) Lagerstedt CI, OlssonCG, Faghter BO, et al:Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2:515-518, 1985
 
35) 石原 康守他:保存療法特に抗凝固線溶療法を施行した下肢深部静脈血栓症の遠隔成績について. 静脈学 9:23-29, 1998
 
36) 広川 雅之:深部静脈血栓症の検討-とくに長期予後に関して-. 日血外会誌 11:1-6, 2002
 
P.171 掲載の参考文献
1) Issemann I, Green S:Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferator. Nature 347:645-650, 1990.
PubMed
2) Mangelsdorf D. J, Thummel C, Beato M, et al. The nuclear receptor superfamily:the second decade. Cell 83:835-839, 1995.
PubMed
3) Kliewer S. A, Forman B. M, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U.S.A. 91:7355-7359, 1994.
PubMed
4) Sher T, Yi H.-F, McBride OW, et al. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598-5604, 1993.
PubMed
5) He T. C, Chan T.A, Vogelstein B, et al. PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-45, 1999.
 
6) Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol 20:5119-28, 2000.
PubMed
7) Tontonoz P, Hu E, Graves RA, et al. mPPAR y2:tissue-specific regulator of an adypocyte enhancer. Gene Dev 8:1224-1234, 1994.
 
8) Fajas L, Fruchart J.C, Auwerx J. PPAR y3 mRNA:a distinct mRNA subtype transcribed from an independent promoter. FEBS Lett 438:55-60, 1998.
 
9) Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs):Tissue distribution of PPAR-a,-B, and-yin the adult rat. Endocrinol 137:354-366, 1996.
 
10) Bishop-Bailey D, Hla, T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-12,14-prostaglandin J2. J Biol Chem 274:17042, 1998.
 
11) Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273:25573-25580, 1998
PubMed
12) Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 354:141, 1999.
PubMed
13) Huang JT, Welch JS, Ricote M, et al. Links Interleukin-4-dependcnt production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400 (6742):378-82, 1999.
 
14) Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation:PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164:1364-1371, 2000.
PubMed
15) Chtanova T, Kemp RA, Sutherland AP, et al. Gene microarrays reveal extensive differential gene expression in both CD4 (+) and CD8 (+) type 1 and type 2 T cells. J Immunol. 167:3057-3063, 2001.
PubMed
16) Gosset P, Charbonnier AS, Delerive P, et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 31:2857-2865, 2001.
PubMed
17) Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 166:7128-7135, 2001.
 
18) Padilla J, Kaur K, Harris SG, et al. PPAR-gamma-mediated regulation of normal and malignant B lineage cells. Ann N Y Acad Sci. 905:97-109, 2000.
PubMed
19) Ricote M., Li A.C., Willson T.M, et al. The peroxisome proliferator-activated receptor-y is a negative regulator of macrophage activation. Nature 391:79, 1998.
PubMed
20) Jiang C. Ting A. T, Seed B. PPAR-y agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82, 1998.
PubMed
21) Kintscher U, Goetze S, Wakino S, et al. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol. 401:259-270, 2000.
PubMed
22) Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169 (3):453-459, 2001.
PubMed
23) Ntoik S., Xu M, Spiegelman. PPARy induces cell cycle withdrawal:inhibition of E2F/DP DNA binding activity via down-regulation of PP2A. Genes Dev 11:1987, 1997.
 
24) Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-δ 12,14-prostaglandin J2. J Biol Chem 274:17042, 1998.
 
25) Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19:2094-2104, 1999
 
26) Xin X., Yang S., Kowalski J. et al. Peroxisome proliferator-activated receptor y ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116, 1999.
 
27) Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270:400, 2000.
PubMed
28) Inoue Ki, Kawahito Y, Tsubouchi Y, et al. Expression of Peroxisome Proliferator-Activated Receptor gamlna in Renal Cell Carcinoma and Growth Inhibition by Its Agonists. Biochem Biophys Res Commun 287:727, 2001.
 
29) Kremer JM, Lawrence DA, Petrillo GF, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum 38:1107-1114, 1995.
PubMed
30) Kawahito Y, Kondo M, Tsubouchi Y, et al. 15-deoxy-Delta (12, 14)-PGJ (2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106:189, 2000.
PubMed
31) Yamasaki S, Nakashima T, Kawakami A, et al. Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway. Clin Exp Immunol 129:379-384, 2002,
PubMed
32) Setoguchi K, Misaki Y, Terauchi Y, et al. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest 108:1667, 2001.
PubMed
33) Castrillo A, Mojena M, Hortelano S, et al. Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796, 449. Comparison with the effects of 15-deoxy-delta (12, 14)-prostaglandin J (2). J Biol Chem 276:34082, 2001.
PubMed
34) Tsubouchi Y, Kawahito Y, Kohno M, et al. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta (12, 14)-prostaglandin J2. Biochem Biophys Res Commun 283:750, 2001.
PubMed
35) Subbaramaiah K, Lin DT, Hart JC, et al. Peroxisome proliferator-activated receptor gamma ligands supprcss the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 276:12440-12448, 2001.
PubMed
36) Inoue H, Tanabe T, Ulnesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 275:28028-28032, 2000.
 
37) Pontsler AV, St Hilaire A, Marathe GK, et al. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem. 277:13029-13036, 2002.
PubMed
38) Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent action of cyclooxygenase inhibitors. FASEB J. 15:2057, 2001.
PubMed
39) Hirai H, Tanaka K, Takano S, et al. Cutting edge:agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol. 168:981-985, 2002.
PubMed
40) Kalajdzic T, Faour WH, He QW, et al. Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts:evidence for receptor antagonism. Arthritis Rheum. 46:494-506, 2002.
PubMed
41) Yamazaki R, Kusunoki N, Matsuzaki T, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 302:18-25, 2002.
PubMed
42) Monneret G, Li H, Vasilescu J, et al. 15-Deoxy-delta 12, 14-prostaglandins D2 and J2 are potent activators of human eosinophils. J Immunol 168:3563-3569, 2002.
PubMed
43) Willoughby DA, Moore A. R, Colville-Nash P. R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 355:646, 2000.
PubMed
44) Tanioka T, Nakatani Y, Semmyo N, et al. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275:32775-32782, 2000.
PubMed
45) Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs:cloning, structure, and expression. Proc Natl Acad Sci USA. 99:13926-31, 2002.
PubMed
46) Maxey KM, Hessler E, MacDonald J, et al. The nature and composition of 15-deoxy-Delta (12, 14) PGJ (2). Prostaglandins Other Lipid Mediat. 62:15-21, 2000.
PubMed
47) Fahmi H, Pelletier JP, Mineau F, et al. 15d-PGJ (2) is acting as a ldual agenti on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 10:845-848, 2002.
 
48) Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2 J Cell Biochem 74:357-371, 1999.
PubMed
49) Mbalaviele G, Abu-Amer Y, Meng A, et al. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 275:14388, 2000.
PubMed
50) Okazaki R, Toriumi M, Fukumoto S, et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140:5060-5065, 1999.
PubMed
51) Fahmi H., Di Battista J.A., Pelletier J-P, et al. Peroxisome proliferator-activated receptor y activators inhibit interleukin-1 B-induced nitric oxide and metalloproteinase 13 production in human chondrocytes. Arthritis and Rheum. 44:595, 2001.
 
52) Sabatini M, Bardiot A, Lesur C, et al. Effects of agonists of peroxisome proliferator-activated receptor gamma on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro. Osteoarthritis Cartilage 10:673-679, 2002.
PubMed
53) Fahmi H, Pelletier JP, Mineau F, Martel-Pelletier J. 15d-PGJ (2) is acting as a 'dual agent' on the regulation of COX-2 expression in hurnan osteoarthritic chondrocytes. Osteoarthritis Cartilage 10:845-848, 2002.
 
P.178 掲載の参考文献
1) 竹原和彦:創傷治癒と細胞成長因子. 皮膚臨床 35:1357-1362, 1993.
 
2) 竹原和彦:増殖因子の臨床応用-損傷修復を中心に. 医学とサイエンスシリーズ 細胞増殖因子の作用と疾患(宮園浩平編), pp116-121, 東京, 羊土社, 1998.
 
P.183 掲載の参考文献
1) Lipson SJ, Muir H:Proteoglycans in experimental intervertebral disc degeneration. Spine 6:194-210, 1981
PubMed
2) Thompson JP, Oegema TR, Bradford DS:Stimulation of mature canine intervertebral disc by growth factors. Spine 16:253-260, 1991
PubMed
3) Hannallah D, Peterson B, Lieberman JR, et al:Gene therapy in orthopaedic surgery. J Bone Joint Surg 84-A:1046-1061, 2002
 
4) Nishida K Gilbertson LG, Evans CH, et al:Adenovirus mediated gene transfer to nucleus pulposus cells:Implications for the treatment of intervertebral disc degeneration. Spine 23:2437-2443, 1998
PubMed
5) Nishida K, Kang JD, Gilbertson LG, et al:Modulation of the biological activity of the rabbit intervertebral disc by gene therapy:an in-vivo study of adenovirus-mediated transfer of the human TGF-B1 encoding gene. Spine 24:2419-2425, 1999
 
6) Takada T, Nishida K, Doita M, et al:Fas ligand exists on intervertebral disc cells:a potential molecular mechanism for immune privilege of the disc. Spine 27:1526-1530, 2002
 
7) 西田康太郎, 土井田稔, 黒坂昌弘:遺伝子治療. 脊椎・脊髄外科の最前線 (菊池晴彦, 平林 洌, 監修), pp1-6, 東京, 先端医療技術研究所, 2002
 
P.192 掲載の参考文献
1) 骨粗鬆症の治療 (薬物療法) に関するガイドライン 2002年度改訂版. Osteoporosis Japan Newsletter 5 (折茂 肇監修), pp2-15, 2002
 
2) 望月善子:更年期と骨粗鬆症. 産婦人科治療 84:401-405, 2002
Medical*Online
3) Pacifci R:Estrogen, cytokine, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11:1043-1051, 1996
 
4) Manolagas SC, Jilka RL:Bone marrow, cytokines, and bone remodeling:emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311, 1995
PubMed
5) 福本誠二:骨粗鬆症の病態生理と診断. 今日の治療 8:864-857, 2000
 
6) 高松 潔, 大田博明:閉経後骨粗鬆症. 今月の治療 8:34-43, 2000
 
7) Christiansen C, Christiansen MS, Transb φ 1 I:Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1:459-461, 1981
 
8) Writing group for the Women's Health Initiative Investigateors:Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-333, 2002
 
9) Delmas PD, Bjarnason NH, Mitlak BH, et al:Effects of Raloxyfene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women. N Engl J Med 337:1641-1647, 1997
 
10) 牛山敏夫:骨粗鬆症とselective estrogen receptor modulators. リウマチ病セミナーXI (七川歡次監修), pp103-111, 大阪, 永井書店, 2000
 
11) Sato M, Grasser W, Endo N:Bisphosphonate action:Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2205-2105, 1991
 
12) Cecchini MG, Fleisch H:Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5:1019-1027, 1990
PubMed
13) Huhghs DE, Wright KR, Uy HI:Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Bone Miner Res 10:1478-1487, 1995
 
14) Leberman UA, Weiss SA, Broll J:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443, 1995
 
15) Nishikawa T:Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone 27:647-654, 2000
 
16) Lee K, Deeds JD, Bond AT, et al:In situ localization of PTH/PTHrP receptor mRNA in the bone of fetal and young rats. Bone 14:341-345, 1993
 
17) Tam CS, Heersche JNM, Murray TM, et al:Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action:Differential effects of intermittent and continuous administration. Endocrinology 110:506-512, 1982
 
18) 杉本利嗣:PTH注. Nippon Rinsho 60:544-551, 2002
 
19) Riggs BL, Tsai KS, Mann KG:Evidence that serum Gla-protein is a measure of bone formation, but not of bone resorption. Calcif Tissue Int 36:497-502, 1984
 
20) Zhang L, Endo N, Yamaoto N, et al:Effects of single and concurrent intermittent administration of huhman PTH (1-34) and incadronate on cancellous and cortical bone of femoral neck in ovariectomized rats. Tohoku J Exp Med 186:131-141, 1998
 
21) Cosman F, Nieves J, Woelfert L, et al:Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13:1051-1055, 1998
PubMed
22) Neer RM, Arnaud CD, Zanchetta JR, et al:Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441, 2001
PubMed
23) Vahle JL, Sato M, Long GG, et al:Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safty. Toxicol Pathol 30:312-321, 2002
 
24) 中村利孝:骨粗鬆症に対するPTH治療のEBM. CLINICAL CALCIUM 13:46-53, 2003
 
25) Rittmaster RS, Bolognese M, Ettinger MP, et al:Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134, 2000
PubMed
26) Okimoto N, Tsurukami H, Okazaki Y et al:Effects of a weekly injection of human parathyroid hormone (1-34) and withdrawal parathyroid hormone (1-34) and withdrawal on bone mass, strength, and turnover in mature ovariectomized rats. Bone 22:523-531, 1998
 
27) Plotkin H, Gundberg C, Mitnick M, et al:Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide (1-36) in hunans:potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83:2786-2791, 1998
 
28) Fujita T, Inoue T, Morii H, et al:Effect of intermittent weekly dose of human Parathroid hormone (1-34) on osteoporosis:a randomized duble-masked prostective study using three dose levels. Ostoporosis Int 9:296 306, 1999
 
29) Mashiba T, Tanizawa T, Takano Y, et al:Ahistomorphometric study on effects of single human PTH (1-34) and bisphosphonate on tibial metaphysic in ovarectomized rats. Bone 17:273S-278S, 1995
 
30) Bradbeer JN, Arlot ME, Mainier PJ, et al:Traetment of osteoporosis with parathyroid peptide-(hPTH1-34) and oestrogen:increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol 37:282-289, 1992
 
31) Neer RM, Slovik D, Doppelt S, et al:The use of parathyroid hormone plus 1, 25-dihydroxyvitamin D to increase trabecular bone in osteoporotic men and postmenopausal women. In:Christiansen C Johansen JS, Riis BJ, ed. Osteoporosis 1987. Copenhagen:Osteopress, 823-835, 1987
 
32) Hodsman AB, Fraher U, Watson PH, et al:A raal on bone mass, strength, and turnover in mature ovariectomized rats. Bone 22:523-531, 1998
 
33) Delmas PD, Vergnaud P, Arlot ME, et al:The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-Is activated resorption a prerequisite for the in vivo effect of PTH on formation in remodeling system? Bone 16:603-610, 1995
 
34) Lindsay R, Nieves J, Formica C, et al:Randomised controlled study of effects of parathyroid hormone onvertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555, 1997
PubMed
35) Roe EB, et al:Treatment of postmenopausal osteoporosis with hPTH1-34 and estrogen. Proc of the 81st Annual Meet of The Endocrine Soc, p58, 1999
 
36) Body, Gaich GA, Scheele WH, et al:A randomized double-blind trial to compare the efficacy of teriparatide recombinant human parathyroid hormone (1-34) with Alendronate in postmenopausal women with osteoporosis. J Clin Encrinol Metab 87:4528-4535, 2002
 
37) Ishizuya T, Yokose S, Hori M, et al:Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99:2961-2970, 1997
 
P.202 掲載の参考文献
1) ICSD International classification of sleep disorders, 1990:Diagnostic and cording manual. Diagnostic Classification Steering Comittee, Thorpy MJ, Chairman. Rochester, Minnesota:American Sleep Disorders Association, 396. (日本睡眠学会診断分類委員会訳, 1994:睡眠障害国際分類診断とコード手引き, 278.)
 
2) Guilleminault C, Tilkian A, Dement WC:The sleep apnea syndromes. Annu Rev Med 27:465-484, 1976
PubMed
3) Guilleminault C, Stoohs R, Clerk A, et al:A cause of excessive daytime sleepiness:The upper airway resistance. Chest 104:781-787, 1993
 
4) 陳 和夫:生活習慣病としてのOSAHS. 綜合臨牀 52:3047-3053, 2003.
Medical*Online
P.214 掲載の参考文献
1) Wolfe F, Zwillich SH:The long-term outcomes of rheumatoid arthritis. A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheumatism 41:1072-1082, 1998
 
2) Massardo L, Gabriel SE, Crowson CS, et al:A population based assessment of the use of orthopecid surgery in patient with rheumatoid arthritis. J Rheumatology 29:52-67, 2002
PubMed
3) 小松原良雄:慢性関節リウマチ早期診断の有効性, リウマチ病セミナーX (七川歡次監修), pp53-60, 大阪, 永井書店, 2001
 
4) 前田 晃, 村田紀和, 小松原良雄:若年性関節リウマチの長期追跡調査, 平成10年度特定疾患調査研究結果報告書, 骨 42-45, 大阪府保健衛生部, 1999
 
5) 前田 晃:JCA1998, リウマチ病セミナーX (七川歡次監修), pp4658, 大阪, 永井書店, 1999
 
6) ACR subcommittee on rhetlmatoid arthritis guildine. Guidelines for the management of rheumatoid arthritis 2002 Update, Arthritis Rheumatism 46:328-346, 2002
 
7) 日本リウマチ友の会:リウマチの医療-手術-, 2000年リウマチ白書, リウマチ患者の実態 (総合編), pp46-50, 流211, 2000
 
P.222 掲載の参考文献
1) Eisenberg DM, Kessler RC, Foster C, et al:Unconventional medicine in the United States:prevalence, costs, and patterns of use. N Engl J Med 328:246-252, 1993
 
2) Eisenberg DM, Davis RB, Ettner SL, et al:Trends in alternative medicine use in the United States, 1990-1997:results of a follow-up national survey. JAMA 280:1569-1575, 1998
PubMed
3) Vickers A:Use of complernentary therapies. BMJ 309:161, 1994
 
4) Ernst E, White A:The BBC survey of complementary medicine use in the UK. Complement Ther Med 8:32-36, 2000
PubMed
5) National Center for Complementary and Alternative Medicine ホームページ. http://nccam.nih.gov/
 
6) Mills SY:The House of Lords report on complementary medicine:a summary. Complement Ther Med 9:34-39, 2001
PubMed
7) Yamashita H, Tsukayama H, Sugishita C:Popularity of complementary and alternative medicine in Japan:a telephone survey. Complement Ther Med 10:84-93, 2002
PubMed
8) 山下 仁, 津嘉山洋:日本における相補代替医療の普及状況-「バブル」「玉石混淆」「エビデンス」-. 医道の日本 710:151-157, 2003
 
9) Lim BM, Min JH, Jang US, et al:The utilization of the complementary and alternative medicine in Korea. The llth International Congress of Oriental Medicine (Abstracts) 29, 2001
 
10) 日本リウマチ友の会. 2000年リウマチ白書-リウマチ患者の実態<資料編>-. 流211 (付録). 30, 2000
 
11) 長岡章平, 大野美香子, 西林保朗:慢性関節リウマチにおける代替医療. リウマチ科 25:452-456, 2001
 
12) 梶山 浩, 赤真秀人, 滝沢健司ら:慢性関節リウマチ患者における補完・代替療法の利用頻度. リウマチ 42:351, 2002
 
13) 赤真秀人:RAと代替療法. Medicina 38:452-454, 2001
 
14) 浦田幸朗, 丸岡浩誌, 赤真秀人:代替医療による関節疾患へのアプローチ. 治療 84:59-63, 2002
 
15) Ernst E:Usage of complementary therapies in rheumatology:a systematic review. Clin Rheumatol 17:1301-305, 1998
 
16) 山下 仁, 津嘉山洋, 丹野恭夫:エビデンスにもとつく補完代替医療-補完代替医学研究の最近の動向-. 日本東洋医学雑誌 51:469-478, 2000
 
17) 山下 仁, 津嘉山洋:相補代替医療:バブル突入の予感 (上)-欧米と日本の教育・研究・政策の現状-. メディカル朝日2月号, pp52-54, 2002
 
18) 山下 仁:世界の代替医療事情-ヨーロッパの代替医療-. 漢方と最新治療 11:19-25, 2002
 
19) Ernst E:Complementary therapies for rheumatoid arthritis. Focus Altern Complement Ther (FACT) 6:247-250, 2001
 
20) Vickers A, Goyal N, Harland R, et al:Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clin Trials 19:159-166, 1998
 
21) Rheumatoid arthritis. In:The Desktop Guide to Complementary and Alternative Medicine (Ed, Ernst E), pp 338-344, London, Mosby (Harcourt Health Sciences), 2001
 
22) Kjeldsen-Kragh J, Haugen M Borchgrevink CF, et al:Controlled trial of fasting and on-year vegetarian diet in rheumatoid arthritis. Lancet 338:899-902, 1991
PubMed
23) Miller H, de Toledo FW, Resch KL:Fasting followed by vegetarian diet in patients with rheumatoid arthritis:a systematic review. Scand J Rheumatol 30:110, 2001
 
24) Astin JA, Beckner W, Soeken K, et al:Psychological interventions for rheumatoid arthritis:a meta-analysis of randomized controlled trials. Arthritis Rheum 47:291-302, 2002
PubMed
25) Superio-Cabuslay E, Ward MM, Lorig KR:Patient education interventions in osteoarthritis and rheumatoid arthritis:a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment. Arthritis Care Res 9:292-301, 1996
PubMed
26) Morgan SL, Baggott JE, Lee JY, et al:Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis:implications for cardiovascular disease prevention. J Rheumatol 25:441-446, 1998
PubMed
27) Otis Z Shea B, Suarez Almazor M, et al:Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). In:The Cochrane Library, Issue 3, Oxford:Update Software, 2002
 
28) Morgan SL, Baggott JE, Vaughn WH, et al:Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 121:833-841, 1994
PubMed
29) 田中泰史:メトトレキサートと葉酸. リウマチ病セミナーIX (七川歡次監修), pp225-236, 大阪, 永井書店, 1998
 
30) Little C, Parsons T:Herbal therapy for treating rheumatoid arthritis (Cochnare Review). In:The Cochrane Library, Issue 3, Oxford:Update Software, 2002
 
31) 谷口敦夫:慢性関節リウマチの食事療法. リウマチ病セミナーI (七川歡次監修), pp3-11, 大阪, 永井書店, 1990
 
32) Fortin PR, Lew RA, Liang MH, et al:Validation of a meta-analysis:the effects of fish oil in rheumatoid arthritis. J Clin Epidemiol 48:1379-1390, 1995
PubMed
33) 日本東洋医学会EBM特別委員会:2002年中間報告漢方治療におけるEBM. 日本東洋医学会 53 (5号別冊), 2002
 
34) 山下 仁, 津嘉山洋:鍼灸の臨床試験. 医学のあゆみ 203:503-507, 2002
Medical*Online
35) Ernst E, White A:鍼治療の科学的根拠-欧米のEBM研究者による臨床評価-(山下仁, 津嘉山洋, 訳), 横浜, 医道の日本社, 2001
 
36) 岩本光弘, 天川浩彦, 内山真由美ら:慢性関節リウマチ患者の鍼灸マッサージに対する意識調査. 日本温泉気候物理医学会雑誌 56:50, 1992
 
37) 津嘉山洋, 山下 仁:鍼の臨床試験-その方法論・実践における課題-. 臨床評価 30:43-51, 2002
 
38) Lautenschlager J:Acupuncture in treatment of inflammatory rheumatic diseases. Z Rheumatol 56:8-20, 1997
PubMed
39) David J, Townsend R, Sathanathan R, et al:The effect of acupuncture on patients with rheumatoid arthritis:a randomized, placebo-controlled cross-over study. Rheumatology (Oxford) 38:364-369, 1999
 
40) Tukmachi E:Acupuncture and rheumatoid arthritis. Rheumatology 39:1153-1165, 2000
PubMed
41) 粕谷大智:鍼灸治療が慢性関節リウマチのQOLに及ぼす効果. 医道の日本 699:24-33, 2002
 
42) 吉川 信:慢性関節リウマチ患者に対する鍼灸治療効果の検討 (1). 医道の日本 706:37-52, 2002
 
43) 吉川 信:慢性関節リウマチ患者に対する鍼灸治療効果の検討 (2). 医道の日本 707:25-44, 2002
 
44) 厚生労働省:研究事業 (厚生労働科学研究費補助金). 厚生労働省ホームページ (http://www.mhlw.go.jp/wp/kenkyu/html):Accessed January 30, 2003
 
45) Brosseau L, Welch V, Wells G, et al:Low level laser therapy (Classes I, II, III) for treating rheumatoid arthritis (Cochrane Review). In:The Cochrane Library, Issue 3, Oxford, Update Software, 2002
 
46) 山下 仁, 津嘉山洋, 丹野恭夫ら:鍼灸の副作用. 医学のあゆみ 196:765-767, 2001
Medical*Online
47) Yamashita H, Tsukayama H, Tanno Y, et al:Adverse events in acupuncture and moxibustion treatment:a six-year survey at a national clinic in Japan. J Altern Complement Med 5:229-236, 1999
 
48) 坂井友実, 長野忠良, 白坂 昭ら:慢性関節リウマチに対するマッサージの臨床的研究. 日本手技療法学会雑誌 1:2-5, 1990
 
49) 高尾主税, 水出靖, 粕谷大智ら:慢性関節リウマチに対するマッサージの臨床的研究. 日本温泉気候物理医学会雑誌 56:49-50, 1992
 
50) Verhagen AP, de Vet HCW, de Bie RA, et al:Balneotherapy for rheumatoid arthritis and osteoarthritis (Cochrane Review). In:The Cochrane Library, Issue 3, Oxford:Updated Software, 2002
 
P.236 掲載の参考文献
1) Hamalainen M:Epidemiology of upper limb joint affections in rheumatoid arthritis. In Rheumatoid arthritis:current trends in diagnostics, conservative treatment, and surgical reconstruction (Eds, Baumgartner H, Dvorak J, Grob D, et al), pp 158-161, Stuttgart, Georg Thieme Verlag, 1995
 
2) 石川 肇, 村澤 章, 羽生忠正:リウマチ手に対する機能再建術. 関節外科 18:41-48, 1998
 
3) 阿部正人:慢性関節リウマチの装具療法-指関節を中心に患者教育について-. 日本義肢装具学会誌 15:141-145, 1999
 
4) 南川義隆, 斎藤貴徳, 苗加康男, ら:リウマチ手の変形に対する装具療法-Swan-neck変形に対するRing type splintを中心に-. 日関外誌 4:325-332, 1985
 
5) 戸島忠人, 浜田良機, 堀内忠一, ら:スポーツによる遠位饒尺関節障害に対する治療法. 骨・関節・靭帯 9:121-128, 1996
 
6) 松元義彦, 石峰昌雄, 福迫剛, ら:オペロンを用いたリストサポーターの紹介. 第3回RAのリハビリ研究会誌 10:27-39, 1988
 
7) Cytowicz-Karpilowska W, Karpilowski B, et al:The influence of a joint orthosis on the grip force of the rheumatoid hand. Clin Rheumatol 18:373-384, 1999
 
8) Ishikawa H, Murasawa A, Suzuki A, et al:The Senami Wrist Supporter for patients with rheumatoid arthritis. Mod Rheumatol 10:155-159, 2000
PubMed
9) Larsen A, Dale K, Eek M:Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18:481-491, 1977
PubMed
10) Stem EB, Ytterberg SR, Krug HE, et al:Immediate and short-term effects of three commercial wrist extensor orthoses on grip strength and function in patients with rheumatoid arthritis. Arthritis Care Res 9:42-50, 1996.
 
11) Nordenski_ld U:Elastic wrist orthoses, reduction of pain and increase in grip force for women with rheumatoid arthritis. Arthritis Care Res 3:158-162, 1990
 
12) Pagnotta A, Baron M, Korner-Bitensky N:The effect of a static wrist orthosis on hand function in individuals with rheumatoid arthritis. J Rheumatol 25:879-885, 1998.
PubMed
13) 田島規子:装具療法. 関節外科 16:79-85, 1997
 
14) Feinberg J, Brandt KD:Use of resting splints by patients with rheumatoid arthritis. Am J Occup Ther 35:173-178, 1981
PubMed
15) Nicholas JJ, Gruen H, Weiner G, et al:Splinting in rheumatoid arthritis:I. factors affecting patient compliance. Arch Phys Med Rehabil 63:92-94, 1982.
PubMed
16) Feinberg J:Effect of the arthritis health professional on compliance with use of resting hand splints by patients with rheumatoid arthritis. Arthritis Care Res 5:17-23, 1992
PubMed
17) Chow JA, Dovelle S, Thomes LJ, et al:A comparison of results of extensor tendon repair followed by early controlled mobilization versus static immobilization. J Hand Surg 14B:18-20, 1989
 
18) Boozer JA, Sanson MS, Soutas-Little RW, et al:Comparison of the biomechanical motions and forces involved in high-profile versus low-profile dynamic splinting. J Hand Ther 7:171-182, 1994
PubMed
19) Skirven T:Rehabilitation following surgery for the distal radioulnar joint. Techniques in Hand and Upper Extremity Surgery 1:219-225, 1997
PubMed
P.242 掲載の参考文献
1) Urist MR:Bone formation by autoinduction. Science 150:893-899, 1965
PubMed
2) 木村友厚, 妻木範行, 松井好人:骨軟骨疾患と遺伝子異常. リウマチ病セミナーVII (七川歡次監修), pp71-77, 大阪, 永井書店, 1996
 
3) Savarirayan R, White SM, Goodman FR, et al:Broad phenotypic spectrum caused by an identical heterozygous CDMP-l mutation in three unrelated families. Am J Med Genet 117A (2):136-42, 2003
 
4) 石澤命仁:Myositis ossificans. リウマチ病セミナーXIV (七川歡次監修), pp 29-35, 大阪, 永井書店, 2003
 
5) Reddi AH:bone morphogenetic proteins:from basic science to clinical application. J Bone Joint Surg 83-A, Suppl 1:S1-6, 2001
 
6) Burkus JK, Transfeldt EE, Kitchel SH, et al:Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 27:2396-2408, 2002
PubMed
7) Saito N, Okada T, Horiuchi H, et al:A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat Biotechnol 19:332-335, 2001
 

手術

P.251 掲載の参考文献
1) Larsen A, Dale K, Eek M:Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18:481-491, 1997
 
2) Morrey BF:Semi-constraind arthroplasty for the treatment of rheumatoid arthritis of the elbow. J Bone J Surg 74-A:479-499, 1992
 
3) Inoue H, Yokoyama Y, Tanabe G:Alumina ceremic elbow prosthesis. Rheumatology 15:78-87, 1991
 
4) 茂山幸雄, 井上 一:KC-1型 (京セラ) 人工肘関節. 関節外科 16:1059-1065, 1997
 
5) Hagena FW:Synovectomy of the elbow. A Review of the literature and results of an ERASS multicenter study. Rheumatology 15:621, 1991
 
6) Kankaanpaa U:Vainio arthroplasty of the elbow joint. Rheumatology 15:47-51, 1991
 
7) Kudo H, Iwano K, Watanabe S:Total elbow arthroplasty of the rheumatoid elbow with a hingeless prosthesis. J Bone & Joint Surg 62-A:277-285, 1980
PubMed
8) 工藤 洋:工藤式 人工肘関節. 関節外科 16:1039-1048, 1997
 
9) Souter WA:A new approach to elbow Arthroplasty. Eng Med 10:59-64, 1981
 
10) Gschwend N, Scheier H, Baehler AR:Long-term results of the GSB-III elbow arthroplasty. J Bone Surg 81-B:1005-1012, 1999
 
P.260 掲載の参考文献
1) Siebert W, Mai S, Kober R, et al:Technique and first clinical results of robot-assisted total knee replacement. Knee 9:173-180, 2002.
PubMed
2) Borner M, Bauer A, Lahmer A. [Computer-assisted robotics in hip endoprosthesis implantation]. Unfallchirurg 100:640-645, 1997.
PubMed
3) DiGioia AM, 3rd, Jaramaz B, Colgan BD:Computer assisted orthopaedic surgery. Image guided and robotic assistive technologies. Clin Orthop:8-16, 1998.
PubMed
4) Radermacher K, Portheine F, Anton M, et al:Computer assisted orthopaedic surgery with image based individual templates. Clin Orthop:28-38, 1998.
PubMed
5) Birke A, Reichel H, Hein W, et al:ROBODOC; a path into the future of hip endoprosthetics or an investment error? Z Orthop Ihre Grenzgeb 138:395-401, 2000.
PubMed
6) Haraguchi K, Sugano N, Nishii T, et al:Comparison of fit and fill between anatomic stem and straight tapered stem using virtual implantation on the ORTHODOC workstation. Comput Aided Surg 6:290-296, 2001.
PubMed
7) Hagio, K. Sugano, N. Takashina, et al:Effectiveness of the ROBODOC system in reventing intraoperative pulmonary embolism. Acta Orthop Scand 74:264-269, 2003.
 
8) Sugano N, Ohzono K, Nishii T, et al.:Computed-tomography-based computer preoperative planning for total hip arthroplasty. Comput Aided Surg 3:320-324, 1998.
PubMed
9) Jenny JY, Boeri C:Computer-assisted implantation of total knee prostheses:a case-control comparative study with classical instrumentation. Comput Aided Surg; 6(4):217-20, 2001
PubMed
10) Delp SL, Stulberg SD, Davies B, et al:Computer assisted knee replacement. Clin Orthop:49-56, 1998.
PubMed
11) Yoshino N, Takai S, Ohtsuki Y, et al:Computed tomography measurement of the surgical and clinical transepicondylar axis of the distal femur in osteoarthritic knees. J Arthroplasty 16:493-497, 2001.
PubMed
12) Aglietti P and Buzzi R. Posteriorly stabilised total-condylar knee replacement. Three to eight yearsi follow-up of 85 knees. J Bone Joint Surg Br 70:211-216, 1988.
 
13) Bargren JH, Blaha JD, Freeman MA:Alignment in total knee arthroplasty. Correlated biomechanical and clinical observations. Clin Orthop:178-183, 1983.
PubMed
14) Jaramaz B, DiGioia AM, 3rd, Blackwell M, et al:Computer assisted measurement of cup placement in total hip replacement. Clin Orthop:70-81, 1998.
PubMed
15) Digioia AM, 3rd, Jaramaz B, Plakseychuk AY, et al:Comparison of a mechanical acetabular alignment guide with computer placement of the socket. J Arthroplasty 17:359-364, 2002.
PubMed
16) Griffin FM, Insall JN, and Scuderi GR. Accuracy of soft tissue balancing in total knee arthroplasty. J Arthroplasty 15:970-973, 2000
PubMed

書評

最近チェックした商品履歴

Loading...